Patent Grant
10876114
The present specification is being filed with a Sequence Listing in Computer Readable Form (CFR), which is entitled 11808-364-999_SEQLIST.txt of 128,829 bytes in size and was created Nov. 15, 2018; the content of which is incorporated herein by reference in its entirety.
The invention relates to the field of genetics, more specifically human genetics. The invention in particular relates to modulation of splicing of the human Duchenne Muscular Dystrophy pre-mRNA.
Myopathies are disorders that result in functional impairment of muscles. Muscular dystrophy (MD) refers to genetic diseases that are characterized by progressive weakness and degeneration of skeletal muscles. Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) are the most common childhood forms of muscular dystrophy. They are recessive disorders and because the gene responsible for DMD and BMD resides on the X-chromosome, mutations mainly affect males with an incidence of about 1 in 3500 boys.
DMD and BMD are caused by genetic defects in the DMD gene encoding dystrophin, a muscle protein that is required for interactions between the cytoskeleton and the extracellular matrix to maintain muscle fiber stability during contraction. DMD is a severe, lethal neuromuscular disorder resulting in a dependency on wheelchair support before the age of 12 and DMD patients often die before the age of thirty due to respiratory- or heart failure. In contrast, BMD patients often remain ambulatory until later in life, and have near normal life expectancies. DMD mutations in the DMD gene are characterized by frame shifting insertions or deletions or nonsense point mutations, resulting in the absence of functional dystrophin. BMD mutations in general keep the reading frame intact, allowing synthesis of a partly functional dystrophin.
During the last decade, specific modification of splicing in order to restore the disrupted reading frame of the dystrophin transcript has emerged as a promising therapy for Duchenne muscular dystrophy (DMD) (van Ommen, van Deutekom, Aartsma-Rus, Curr Opin Mol Ther. 2008; 10(2):140-9, Yokota, Duddy, Partidge, Acta Myol. 2007; 26(3):179-84, van Deutekom et al., N Engl J Med. 2007; 357(26):2677-86).
Using antisense oligonucleotides (AONs) interfering with splicing signals the skipping of specific exons can be induced in the DMD pre-mRNA, thus restoring the open reading frame and converting the severe DMD into a milder BMD phenotype (van Deutekom et al. Hum Mol Genet. 2001; 10: 1547-54; Aartsma-Rus et al., Hum Mol Genet 2003; 12(8):907-14.). In vivo proof-of-concept was first obtained in the mdx mouse model, which is dystrophin-deficient due to a nonsense mutation in exon 23. Intramuscular and intravenous injections of AONs targeting the mutated exon 23 restored dystrophin expression for at least three months (Lu et al. Nat Med. 2003; 8: 1009-14; Lu et al., Proc Natl Acad Sci USA. 2005; 102(1):198-203). This was accompanied by restoration of dystrophin-associated proteins at the fiber membrane as well as functional improvement of the treated muscle. In vivo skipping of human exons has also been achieved in the hDMD mouse model, which contains a complete copy of the human DMD gene integrated in chromosome 5 of the mouse (Bremmer-Bout et al. Molecular Therapy. 2004; 10: 232-40; ′t Hoen et al. J Biol Chem. 2008; 283: 5899-907).
Recently, a first-in-man study was successfully completed where an AON inducing the skipping of exon 51 was injected into a small area of the tibialis anterior muscle of four DMD patients. Novel dystrophin expression was observed in the majority of muscle fibers in all four patients treated, and the AON was safe and well tolerated (van Deutekom et al. N Engl J Med. 2007; 357: 2677-86).
Method
In a first aspect, the present invention provides a method for inducing, and/or promoting skipping of at least one of exons 43, 46, 50-53 of the DMD pre-mRNA in a patient, preferably in an isolated cell of a patient, the method comprising providing said cell and/or said patient with a molecule that binds to a continuous stretch of at least 8 nucleotides within said exon. It is to be understood that said method encompasses an in vitro, in vivo or ex vivo method.
Accordingly, a method is provided for inducing and/or promoting skipping of at least one of exons 43, 46, 50-53 of DMD pre-mRNA in a patient, preferably in an isolated cell of said patient, the method comprising providing said cell and/or said patient with a molecule that binds to a continuous stretch of at least 8 nucleotides within said exon.
As defined herein a DMD pre-mRNA preferably means the pre-mRNA of a DMD gene of a DMD or BMD patient.
A patient is preferably intended to mean a patient having DMD or BMD as later defined herein or a patient susceptible to develop DMD or BMD due to his or her genetic background. In the case of a DMD patient, an oligonucleotide used will preferably correct one mutation as present in the DMD gene of said patient and therefore will preferably create a DMD protein that will look like a BMD protein: said protein will preferably be a functional dystrophin as later defined herein. In the case of a BMD patient, an oligonucleotide as used will preferably correct one mutation as present in the BMD gene of said patient and therefore will preferably create a dystrophin which will be more functional than the dystrophin which was originally present in said BMD patient.
Exon skipping refers to the induction in a cell of a mature mRNA that does not contain a particular exon that is normally present therein. Exon skipping is performed by providing a cell expressing the pre-mRNA of said mRNA with a molecule capable of interfering with essential sequences such as for example the splice donor of splice acceptor sequence that required for splicing of said exon, or a molecule that is capable of interfering with an exon inclusion signal that is required for recognition of a stretch of nucleotides as an exon to be included in the mRNA. The term pre-mRNA refers to a non-processed or partly processed precursor mRNA that is synthesized from a DNA template in the cell nucleus by transcription.
Within the context of the invention, inducing and/or promoting skipping of an exon as indicated herein means that at least 1%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more of the DMD mRNA in one or more (muscle) cells of a treated patient will not contain said exon. This is preferably assessed by PCR as described in the examples.
Preferably, a method of the invention by inducing and/or promoting skipping of at least one of the following exons 43, 46, 50-53 of the DMD pre-mRNA in one or more (muscle) cells of a patient, provides said patient with a functional dystrophin protein and/or decreases the production of an aberrant dystrophin protein in said patient and/or increases the production of a functional dystrophin is said patient. Providing a patient with a functional dystrophin protein and/or decreasing the production of an aberrant dystrophin protein in said patient is typically applied in a DMD patient. Increasing the production of a functional dystrophin is typically applied in a BMD patient.
Therefore a preferred method is a method, wherein a patient or one or more cells of said patient is provided with a functional dystrophin protein and/or wherein the production of an aberrant dystrophin protein in said patient is decreased and/or wherein the production of a functional dystrophin is increased in said patient, wherein the level of said aberrant or functional dystrophin is assessed by comparison to the level of said dystrophin in said patient at the onset of the method.
Decreasing the production of an aberrant dystrophin may be assessed at the mRNA level and preferably means that 99%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 10%, 5% or less of the initial amount of aberrant dystrophin mRNA, is still detectable by RT PCR. An aberrant dystrophin mRNA or protein is also referred to herein as a non-functional dystrophin mRNA or protein. A non functional dystrophin protein is preferably a dystrophin protein which is not able to bind actin and/or members of the DGC protein complex. A non-functional dystrophin protein or dystrophin mRNA does typically not have, or does not encode a dystrophin protein with an intact C-terminus of the protein.
Increasing the production of a functional dystrophin in said patient or in a cell of said patient may be assessed at the mRNA level (by RT-PCR analysis) and preferably means that a detectable amount of a functional dystrophin mRNA is detectable by RT PCR. In another embodiment, 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more of the detectable dystrophin mRNA is a functional dystrophin mRNA.
Increasing the production of a functional dystrophin in said patient or in a cell of said patient may be assessed at the protein level (by immunofluorescence and western blot analyses) and preferably means that a detectable amount of a functional dystrophin protein is detectable by immunofluorescence or western blot analysis. In another embodiment, 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more of the detectable dystrophin protein is a functional dystrophin protein.
As defined herein, a functional dystrophin is preferably a wild type dystrophin corresponding to a protein having the amino acid sequence as identified in SEQ ID NO: 1. A functional dystrophin is preferably a dystrophin, which has an actin binding domain in its N terminal part (first 240 amino acids at the N terminus), a cystein-rich domain (amino acid 3361 till 3685) and a C terminal domain (last 325 amino acids at the C terminus) each of these domains being present in a wild type dystrophin as known to the skilled person. The amino acids indicated herein correspond to amino acids of the wild type dystrophin being represented by SEQ ID NO:1. In other words, a functional dystrophin is a dystrophin which exhibits at least to some extent an activity of a wild type dystrophin. “At least to some extent” preferably means at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or 100% of a corresponding activity of a wild type functional dystrophin. In this context, an activity of a functional dystrophin is preferably binding to actin and to the dystrophin-associated glycoprotein complex (DGC) (Aartsma-Rus A et al, (2006), Entries in the leiden Duchenne Muscular Dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule, Muscle Nerve, 34: 135-144). Binding of dystrophin to actin and to the DGC complex may be visualized by either co-immunoprecipitation using total protein extracts or immunofluorescence analysis of cross-sections, from a muscle biopsy, as known to the skilled person.
Individuals or patients suffering from Duchenne muscular dystrophy typically have a mutation in the gene encoding dystrophin that prevent synthesis of the complete protein, i.e of a premature stop prevents the synthesis of the C-terminus. In Becker muscular dystrophy the DMD gene also comprises a mutation compared tot the wild type gene but the mutation does typically not induce a premature stop and the C-terminus is typically synthesized. As a result a functional dystrophin protein is synthesized that has at least the same activity in kind as the wild type protein, not although not necessarily the same amount of activity. The genome of a BMD individual typically encodes a dystrophin protein comprising the N terminal part (first 240 amino acids at the N terminus), a cystein-rich domain (amino acid 3361 till 3685) and a C terminal domain (last 325 amino acids at the C terminus) but its central rod shaped domain may be shorter than the one of a wild type dystrophin (Aartsma-Rus A et al, (2006), Entries in the leiden Duchenne Muscular Dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule, Muscle Nerve, 34: 135-144). Exon skipping for the treatment of DMD is typically directed to overcome a premature stop in the pre-mRNA by skipping an exon in the rod-shaped domain to correct the reading frame and allow synthesis of remainder of the dystrophin protein including the C-terminus, albeit that the protein is somewhat smaller as a result of a smaller rod domain. In a preferred embodiment, an individual having DMD and being treated by a method as defined herein will be provided a dystrophin which exhibits at least to some extent an activity of a wild type dystrophin. More preferably, if said individual is a Duchenne patient or is suspected to be a Duchenne patient, a functional dystrophin is a dystrophin of an individual having BMD: typically said dystrophin is able to interact with both actin and the DGC, but its central rod shaped domain may be shorter than the one of a wild type dystrophin (Aartsma-Rus A et al, (2006), Entries in the leiden Duchenne Muscular Dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule, Muscle Nerve, 34: 135-144). The central rod-shaped domain of wild type dystrophin comprises 24 spectrin-like repeats (Aartsma-Rus A et al, (2006), Entries in the leiden Duchenne Muscular Dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule, Muscle Nerve, 34: 135-144). For example, a central rod-shaped domain of a dystrophin as provided herein may comprise 5 to 23, 10 to 22 or 12 to 18 spectrin-like repeats as long as it can bind to actin and to DGC.
A method of the invention may alleviate one or more characteristics of a myogenic or muscle cell of a patient or alleviate one or more symptoms of a DMD patient having a deletion including but not limited to exons 44, 44-46, 44-47, 44-48, 44-49, 44-51, 44-53 (correctable by exon 43 skipping), 19-45, 21-45, 43-45, 45, 47-54, 47-56 (correctable by exon 46 skipping), 51, 51-53, 51-55, 51-57 (correctable by exon 50 skipping), 13-50, 19-50, 29-50, 43-50, 45-50, 47-50, 48-50, 49-50, 50, 52 (correctable by exon 51 skipping), exons 8-51, 51, 53, 53-55, 53-57, 53-59, 53-60, (correctable by exon 52 skipping) and exons 10-52, 42-52, 43-52, 45-52, 47-52, 48-52, 49-52, 50-52, 52 (correctable by exon 53 skipping) in the DMD gene, occurring in a total of 68% of all DMD patients with a deletion (Aartsma-Rus et al., Hum. Mut. 2009).
Alternatively, a method of the invention may improve one or more characteristics of a muscle cell of a patient or alleviate one or more symptoms of a DMD patient having small mutations in, or single exon duplications of exon 43, 46, 50-53 in the DMD gene, occurring in a total of 36% of all DMD patients with a deletion (Aartsma-Rus et al, Hum. Mut. 2009)
Furthermore, for some patients the simultaneous skipping of one of more exons in addition to exon 43, exon 46 and/or exon 50-53 is required to restore the open reading frame, including patients with specific deletions, small (point) mutations, or double or multiple exon duplications, such as (but not limited to) a deletion of exons 44-50 requiring the co-skipping of exons 43 and 51, with a deletion of exons 46-50 requiring the co-skipping of exons 45 and 51, with a deletion of exons 44-52 requiring the co-skipping of exons 43 and 53, with a deletion of exons 46-52 requiring the co-skipping of exons 45 and 53, with a deletion of exons 51-54 requiring the co-skipping of exons 50 and 55, with a deletion of exons 53-54 requiring the co-skipping of exons 52 and 55, with a deletion of exons 53-56 requiring the co-skipping of exons 52 and 57, with a nonsense mutation in exon 43 or exon 44 requiring the co-skipping of exon 43 and 44, with a nonsense mutation in exon 45 or exon 46 requiring the co-skipping of exon 45 and 46, with a nonsense mutation in exon 50 or exon 51 requiring the co-skipping of exon 50 and 51, with a nonsense mutation in exon 51 or exon 52 requiring the co-skipping of exon 51 and 52, with a nonsense mutation in exon 52 or exon 53 requiring the co-skipping of exon 52 and 53, or with a double or multiple exon duplication involving exons 43, 46, 50, 51, 52, and/or 53.
In a preferred method, the skipping of exon 43 is induced, or the skipping of exon 46 is induced, or the skipping of exon 50 is induced or the skipping of exon 51 is induced or the skipping of exon 52 is induced or the skipping of exon 53 is induced. An induction of the skipping of two of these exons is also encompassed by a method of the invention. For example, preferably skipping of exons 50 and 51, or 52 and 53, or 43 and 51, or 43 and 53, or 51 and 52. Depending on the type and the identity (the specific exons involved) of mutation identified in a patient, the skilled person will know which combination of exons needs to be skipped in said patient.
In a preferred method, one or more symptom(s) of a DMD or a BMD patient is/are alleviated and/or one or more characteristic(s) of one or more muscle cells from a DMD or a BMD patient is/are improved. Such symptoms or characteristics may be assessed at the cellular, tissue level or on the patient self.
An alleviation of one or more characteristics may be assessed by any of the following assays on a myogenic cell or muscle cell from a patient: reduced calcium uptake by muscle cells, decreased collagen synthesis, altered morphology, altered lipid biosynthesis, decreased oxidative stress, and/or improved muscle fiber function, integrity, and/or survival. These parameters are usually assessed using immunofluorescence and/or histochemical analyses of cross sections of muscle biopsies.
The improvement of muscle fiber function, integrity and/or survival may be assessed using at least one of the following assays: a detectable decrease of creatine kinase in blood, a detectable decrease of necrosis of muscle fibers in a biopsy cross-section of a muscle suspected to be dystrophic, and/or a detectable increase of the homogeneity of the diameter of muscle fibers in a biopsy cross-section of a muscle suspected to be dystrophic. Each of these assays is known to the skilled person.
Creatine kinase may be detected in blood as described in Hodgetts et al (Hodgetts S., et al, (2006), Neuromuscular Disorders, 16: 591-602.2006). A detectable decrease in creatine kinase may mean a decrease of 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more compared to the concentration of creatine kinase in a same DMD or BMD patient before treatment.
A detectable decrease of necrosis of muscle fibers is preferably assessed in a muscle biopsy, more preferably as described in Hodgetts et al (Hodgetts S., et al, (2006), Neuromuscular Disorders, 16: 591-602.2006) using biopsy cross-sections. A detectable decrease of necrosis may be a decrease of 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more of the area wherein necrosis has been identified using biopsy cross-sections. The decrease is measured by comparison to the necrosis as assessed in a same DMD or BMD patient before treatment.
A detectable increase of the homogeneity of the diameter of a muscle fiber is preferably assessed in a muscle biopsy cross-section, more preferably as described in Hodgetts et al (Hodgetts S., et al, (2006), Neuromuscular Disorders, 16: 591-602.2006). The increase is measured by comparison to the homogeneity of the diameter of a muscle fiber in a same DMD or BMD patient before treatment. An alleviation of one or more symptoms may be assessed by any of the following assays on the patient self: prolongation of time to loss of walking, improvement of muscle strength, improvement of the ability to lift weight, improvement of the time taken to rise from the floor, improvement in the nine-meter walking time, improvement in the time taken for four-stairs climbing, improvement of the leg function grade, improvement of the pulmonary function, improvement of cardiac function, improvement of the quality of life. Each of these assays is known to the skilled person. As an example, the publication of Manzur at al (Manzur A Y et al, (2008), Glucocorticoid corticosteroids for Duchenne muscular dystrophy (review), Wiley publishers, The Cochrane collaboration.) gives an extensive explanation of each of these assays. For each of these assays, as soon as a detectable improvement or prolongation of a parameter measured in an assay has been found, it will preferably mean that one or more symptoms of Duchenne Muscular Dystrophy or Becker Muscular Dystrophy has been alleviated in an individual using a method of the invention. Detectable improvement or prolongation is preferably a statistically significant improvement or prolongation as described in Hodgetts et al (Hodgetts S., et al, (2006), Neuromuscular Disorders, 16: 591-602.2006). Alternatively, the alleviation of one or more symptom(s) of Duchenne Muscular Dystrophy or Becker Muscular Dystrophy may be assessed by measuring an improvement of a muscle fiber function, integrity and/or survival as later defined herein.
A treatment in a method according to the invention may have a duration of at least one week, at least one month, at least several months, at least one year, at least 2, 3, 4, 5, 6 years or more.
Each molecule or oligonucleotide or equivalent thereof as defined herein for use according to the invention may be suitable for direct administration to a cell, tissue and/or an organ in vivo of individuals affected by or at risk of developing DMD or BMD, and may be administered directly in vivo, ex vivo or in vitro. The frequency of administration of a molecule or an oligonucleotide or a composition of the invention may depend on several parameters such as the age of the patient, the mutation of the patient, the number of molecules (dose), the formulation of said molecule. The frequency may be ranged between at least once in a two weeks, or three weeks or four weeks or five weeks or a longer time period.
A molecule or oligonucleotide or equivalent thereof can be delivered as is to a cell. When administering said molecule, oligonucleotide or equivalent thereof to an individual, it is preferred that it is dissolved in a solution that is compatible with the delivery method. For intravenous, subcutaneous, intramuscular, intrathecal and/or intraventricular administration it is preferred that the solution is a physiological salt solution. Particularly preferred for a method of the invention is the use of an excipient that will further enhance delivery of said molecule, oligonucleotide or functional equivalent thereof as defined herein, to a cell and into a cell, preferably a muscle cell. Preferred excipient are defined in the section entitled “pharmaceutical composition”.
In a preferred method of the invention, an additional molecule is used which is able to induce and/or promote skipping of another exon of the DMD pre-mRNA of a patient. Preferably, the second exon is selected from: exon 6, 7, 11, 17, 19, 21, 43, 44, 45, 50, 51, 52, 53, 55, 57, 59, 62, 63, 65, 66, 69, or 75 of the DMD pre-mRNA of a patient. Molecules which can be used are depicted in any one of Table 1 to 7. This way, inclusion of two or more exons of a DMD pre-mRNA in mRNA produced from this pre-mRNA is prevented. This embodiment is further referred to as double- or multiexon skipping (Aartsma-Rus A, Janson A A, Kaman W E, et al. Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am J Hum Genet 2004; 74(1):83-92, Aartsma-Rus A, Kaman W E, Weij R, den Dunnen J T, van Ommen G J, van Deutekom J C. Exploring the frontiers of therapeutic exon skipping for Duchenne muscular dystrophy by double targeting within one or multiple exons. Mol Ther 2006; 14(3):401-7). In most cases double-exon skipping results in the exclusion of only the two targeted exons from the DMD pre-mRNA. However, in other cases it was found that the targeted exons and the entire region in between said exons in said pre-mRNA were not present in the produced mRNA even when other exons (intervening exons) were present in such region. This multi-skipping was notably so for the combination of oligonucleotides derived from the DMD gene, wherein one oligonucleotide for exon 45 and one oligonucleotide for exon 51 was added to a cell transcribing the DMD gene. Such a set-up resulted in mRNA being produced that did not contain exons 45 to 51. Apparently, the structure of the pre-mRNA in the presence of the mentioned oligonucleotides was such that the splicing machinery was stimulated to connect exons 44 and 52 to each other.
It is possible to specifically promote the skipping of also the intervening exons by providing a linkage between the two complementary oligonucleotides. Hence, in one embodiment stretches of nucleotides complementary to at least two dystrophin exons are separated by a linking moiety. The at least two stretches of nucleotides are thus linked in this embodiment so as to form a single molecule.
In case, more than one compounds or molecules are used in a method of the invention, said compounds can be administered to an individual in any order. In one embodiment, said compounds are administered simultaneously (meaning that said compounds are administered within 10 hours, preferably within one hour). This is however not necessary. In another embodiment, said compounds are administered sequentially.
Molecule
In a second aspect, there is provided a molecule for use in a method as described in the previous section entitled “Method”. A molecule as defined herein is preferably an oligonucleotide or antisense oligonucleotide (AON).
It was found by the present investigators that any of exon 43, 46, 50-53 is specifically skipped at a high frequency using a molecule that preferably binds to a continuous stretch of at least 8 nucleotides within said exon. Although this effect can be associated with a higher binding affinity of said molecule, compared to a molecule that binds to a continuous stretch of less than 8 nucleotides, there could be other intracellular parameters involved that favor thermodynamic, kinetic, or structural characteristics of the hybrid duplex. In a preferred embodiment, a molecule that binds to a continuous stretch of at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 nucleotides within said exon is used.
In a preferred embodiment, a molecule or an oligonucleotide of the invention which comprises a sequence that is complementary to a part of any of exon 43, 46, 50-53 of DMD pre-mRNA is such that the complementary part is at least 50% of the length of the oligonucleotide of the invention, more preferably at least 60%, even more preferably at least 70%, even more preferably at least 80%, even more preferably at least 90% or even more preferably at least 95%, or even more preferably 98% and most preferably up to 100%. “A part of said exon” preferably means a stretch of at least 8 nucleotides. In a most preferred embodiment, an oligonucleotide of the invention consists of a sequence that is complementary to part of said exon DMD pre-mRNA as defined herein. For example, an oligonucleotide may comprise a sequence that is complementary to part of said exon DMD pre-mRNA as defined herein and additional flanking sequences. In a more preferred embodiment, the length of said complementary part of said oligonucleotide is of at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 nucleotides. Preferably, additional flanking sequences are used to modify the binding of a protein to said molecule or oligonucleotide, or to modify a thermodynamic property of the oligonucleotide, more preferably to modify target RNA binding affinity.
A preferred molecule to be used in a method of the invention binds or is complementary to a continuous stretch of at least 8 nucleotides within one of the following nucleotide sequences selected from:
Of the numerous molecules that theoretically can be prepared to bind to the continuous nucleotide stretches as defined by SEQ ID NO 2-7 within one of said exons, the invention provides distinct molecules that can be used in a method for efficiently skipping of at least one of exon 43, exon 46 and/or exon 50-53. Although the skipping effect can be addressed to the relatively high density of putative SR protein binding sites within said stretches, there could be other parameters involved that favor uptake of the molecule or other, intracellular parameters such as thermodynamic, kinetic, or structural characteristics of the hybrid duplex.
It was found that a molecule that binds to a continuous stretch comprised within or consisting of any of SEQ ID NO 2-7 results in highly efficient skipping of exon 43, exon 46 and/or exon 50-53 respectively in a cell and/or in a patient provided with this molecule. Therefore, in a preferred embodiment, a method is provided wherein a molecule binds to a continuous stretch of at least 8, 10, 12, 15, 18, 20, 25, 30, 35, 40, 45, 50 nucleotides within SEQ ID NO 2-7.
In a preferred embodiment for inducing and/or promoting the skipping of any of exon 43, exon 46 and/or exon 50-53, the invention provides a molecule comprising or consisting of an antisense nucleotide sequence selected from the antisense nucleotide sequences depicted in any of Tables 1 to 6. A molecule of the invention preferably comprises or consist of the antisense nucleotide sequence of SEQ ID NO 16, SEQ ID NO 65, SEQ ID NO 70, SEQ ID NO 91, SEQ ID NO 110, SEQ ID NO 117, SEQ ID NO 127, SEQ ID NO 165, SEQ ID NO 166, SEQ ID NO 167, SEQ ID NO 246, SEQ ID NO 299, SEQ ID NO:357.
A preferred molecule of the invention comprises a nucleotide-based or nucleotide or an antisense oligonucleotide sequence of between 8 and 50 nucleotides or bases, more preferred between 10 and 50 nucleotides, more preferred between 20 and 40 nucleotides, more preferred between 20 and 30 nucleotides, such as 20 nucleotides, 21 nucleotides, 22 nucleotides, 23 nucleotides, 24 nucleotides, 25 nucleotides, 26 nucleotides, 27 nucleotides, 28 nucleotides, 29 nucleotides, 30 nucleotides, 31 nucleotides, 32 nucleotides, 33 nucleotides, 34 nucleotides, 35 nucleotides, 36 nucleotides, 37 nucleotides, 38 nucleotides, 39 nucleotides, 40 nucleotides, 41 nucleotides, 42 nucleotides, 43 nucleotides, 44 nucleotides, 45 nucleotides, 46 nucleotides, 47 nucleotides, 48 nucleotides, 49 nucleotides or 50 nucleotides. A most preferred molecule of the invention comprises a nucleotide-based sequence of 25 nucleotides.
Furthermore, none of the indicated sequences is derived from conserved parts of splice junction sites. Therefore, said molecule is not likely to mediate differential splicing of other exons from the DMD pre-mRNA or exons from other genes.
In one embodiment, a molecule of the invention is a compound molecule that binds to the specified sequence, or a protein such as an RNA-binding protein or a non-natural zinc-finger protein that has been modified to be able to bind to the corresponding nucleotide sequence on a DMD pre-RNA molecule. Methods for screening compound molecules that bind specific nucleotide sequences are, for example, disclosed in PCT/NL01/00697 and U.S. Pat. No. 6,875,736, which are herein incorporated by reference. Methods for designing RNA-binding Zinc-finger proteins that bind specific nucleotide sequences are disclosed by Friesen and Darby, Nature Structural Biology 5: 543-546 (1998) which is herein incorporated by reference.
A preferred molecule of the invention binds to at least part of the sequence of SEQ ID NO 2: 5′-AGAUAGUCUACAACAAAGCUCAGGUCGGAUUGACAUUAUUCAUAGCAAG AAGACAGCAGCAUUGCAAAGUGCAACGCCUGUGG-3′ which is present in exon 43 of the DMD gene. More preferably, the invention provides a molecule comprising or consisting of the antisense nucleotide sequence of SEQ ID NO 8 to SEQ ID NO 69. In an even more preferred embodiment, the invention provides a molecule comprising or consisting of the antisense nucleotide sequence of SEQ ID NO 16 and/or SEQ ID NO 65. In a most preferred embodiment, the invention provides a molecule comprising or consisting of the antisense nucleotide sequence of SEQ ID NO 65. It was found that this molecule is very efficient in modulating splicing of exon 43 of the DMD pre-mRNA in a muscle cell and/or in a patient.
Another preferred molecule of the invention binds to at least part of the sequence of SEQ ID NO 3: 5′-UUAUGGUUGGAGGAAGCAGAUAACAUUGCUAGUAUCCCACUUG AACCUGGAAAAGAGCAGCAACUAAAAGAAAAGC-3′ which is present in exon 46 of the DMD gene. More preferably, the invention provides a molecule comprising or consisting of the antisense nucleotide sequence of SEQ ID NO 70 to SEQ ID NO 122. In an even more preferred embodiment, the invention provides a molecule comprising or consisting of the antisense nucleotide sequence of SEQ ID NO 70, SEQ ID NO 91, SEQ ID NO 110, and/or SEQ ID NO 117. In a most preferred embodiment, the invention provides a molecule comprising or consisting of the antisense nucleotide sequence of SEQ ID NO 117. It was found that this molecule is very efficient in modulating splicing of exon 46 of the DMD pre-mRNA in a muscle cell or in a patient.
Another preferred molecule of the invention binds to at least part of the sequence of SEQ ID NO 4: 5′-GGCGGTAAACCGUUUACUUCAAGAGCU GAGGGCAAAGCAGCCUG ACCUAGCUCCUGGACUGACCACUAUUGG-3′ which is present in exon 50 of the DMD gene. More preferably, the invention provides a molecule comprising or consisting of the antisense nucleotide sequence of SEQ ID NO 123 to SEQ ID NO 167 and/or SEQ ID NO 529 to SEQ ID NO 535. In an even more preferred embodiment, the invention provides a molecule comprising or consisting of the antisense nucleotide sequence of SEQ ID NO 127, or SEQ ID NO 165, or SEQ ID NO 166 and/or SEQ ID NO 167. In a most preferred embodiment, the invention provides a molecule comprising or consisting of the antisense nucleotide sequence of SEQ ID NO 127. It was found that this molecule is very efficient in modulating splicing of exon 50 of the DMD pre-mRNA in a muscle cell and/or in a patient.
Another preferred molecule of the invention binds to at least part of the sequence of SEQ ID NO 5: 5′-CUCCUACUCAGACUGUUACUCUGGUGACACAACCUGUGGUUACU AAGGAAACUGCCAUC UCCAAACUAGAAAUGCCAUCUUCCUUGAUG UUGGAGGUAC-3′ which is present in exon 51 of the DMD gene. More preferably, the invention provides a molecule comprising or consisting of the antisense nucleotide sequence of SEQ ID NO 168 to SEQ ID NO 241.
Another preferred molecule of the invention binds to at least part of the sequence of SEQ ID NO 6: 5′-AUGCAGGAUUUGGAACAGAGGCGUCCCCAGUUGGAAGAACUCAU UACCGCUGCCCAAAAUUUGAAAAACAAGACCAGCAAUCAAGAGGCU-3′ which is present in exon 52 of the DMD gene. More preferably, the invention provides a molecule comprising or consisting of the antisense nucleotide sequence of SEQ ID NO 242 to SEQ ID NO 310. In an even more preferred embodiment, the invention provides a molecule comprising or consisting of the antisense nucleotide sequence of SEQ ID NO 246 and/or SEQ ID NO 299. In a most preferred embodiment, the invention provides a molecule comprising or consisting of the antisense nucleotide sequence of SEQ ID NO 299. It was found that this molecule is very efficient in modulating splicing of exon 52 of the DMD pre-mRNA in a muscle cell and/or in a patient.
Another preferred molecule of the invention binds to at least part of the sequence of SEQ ID NO 7: 5′-AAAUGUUAAAGGAUUCAACACAAUGGCUGGAAGCUAAGGAAGAA GCUGAGCAGGUCUUAGGACAGGCCAGAG-3′ which is present in exon 53 of the DMD gene. More preferably, the invention provides a molecule comprising or consisting of the antisense nucleotide sequence of SEQ ID NO 311 to SEQ ID NO 358. In a most preferred embodiment, the invention provides a molecule comprising or consisting of the antisense nucleotide sequence of SEQ ID NO 357. It was found that this molecule is very efficient in modulating splicing of exon 53 of the DMD pre-mRNA in a muscle cell and/or in a patient.
A nucleotide sequence of a molecule of the invention may contain RNA residues, or one or more DNA residues, and/or one or more nucleotide analogues or equivalents, as will be further detailed herein below.
It is preferred that a molecule of the invention comprises one or more residues that are modified to increase nuclease resistance, and/or to increase the affinity of the antisense nucleotide for the target sequence. Therefore, in a preferred embodiment, the antisense nucleotide sequence comprises at least one nucleotide analogue or equivalent, wherein a nucleotide analogue or equivalent is defined as a residue having a modified base, and/or a modified backbone, and/or a non-natural internucleoside linkage, or a combination of these modifications.
In a preferred embodiment, the nucleotide analogue or equivalent comprises a modified backbone. Examples of such backbones are provided by morpholino backbones, carbamate backbones, siloxane backbones, sulfide, sulfoxide and sulfone backbones, formacetyl and thioformacetyl backbones, methyleneformacetyl backbones, riboacetyl backbones, alkene containing backbones, sulfamate, sulfonate and sulfonamide backbones, methyleneimino and methylenehydrazino backbones, and amide backbones. Phosphorodiamidate morpholino oligomers are modified backbone oligonucleotides that have previously been investigated as antisense agents. Morpholino oligonucleotides have an uncharged backbone in which the deoxyribose sugar of DNA is replaced by a six membered ring and the phosphodiester linkage is replaced by a phosphorodiamidate linkage. Morpholino oligonucleotides are resistant to enzymatic degradation and appear to function as antisense agents by arresting translation or interfering with pre-mRNA splicing rather than by activating RNase H. Morpholino oligonucleotides have been successfully delivered to tissue culture cells by methods that physically disrupt the cell membrane, and one study comparing several of these methods found that scrape loading was the most efficient method of delivery; however, because the morpholino backbone is uncharged, cationic lipids are not effective mediators of morpholino oligonucleotide uptake in cells. A recent report demonstrated triplex formation by a morpholino oligonucleotide and, because of the non-ionic backbone, these studies showed that the morpholino oligonucleotide was capable of triplex formation in the absence of magnesium.
It is further preferred that that the linkage between the residues in a backbone do not include a phosphorus atom, such as a linkage that is formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages.
A preferred nucleotide analogue or equivalent comprises a Peptide Nucleic Acid (PNA), having a modified polyamide backbone (Nielsen, et al. (1991) Science 254, 1497-1500). PNA-based molecules are true mimics of DNA molecules in terms of base-pair recognition. The backbone of the PNA is composed of N-(2-aminoethyl)-glycine units linked by peptide bonds, wherein the nucleobases are linked to the backbone by methylene carbonyl bonds. An alternative backbone comprises a one-carbon extended pyrrolidine PNA monomer (Govindaraju and Kumar (2005) Chem. Commun, 495-497). Since the backbone of a PNA molecule contains no charged phosphate groups, PNA-RNA hybrids are usually more stable than RNA-RNA or RNA-DNA hybrids, respectively (Egholm et al (1993) Nature 365, 566-568).
A further preferred backbone comprises a morpholino nucleotide analog or equivalent, in which the ribose or deoxyribose sugar is replaced by a 6-membered morpholino ring. A most preferred nucleotide analog or equivalent comprises a phosphorodiamidate morpholino oligomer (PMO), in which the ribose or deoxyribose sugar is replaced by a 6-membered morpholino ring, and the anionic phosphodiester linkage between adjacent morpholino rings is replaced by a non-ionic phosphorodiamidate linkage.
In yet a further embodiment, a nucleotide analogue or equivalent of the invention comprises a substitution of one of the non-bridging oxygens in the phosphodiester linkage. This modification slightly destabilizes base-pairing but adds significant resistance to nuclease degradation. A preferred nucleotide analogue or equivalent comprises phosphorothioate, chiral phosphorothioate, phosphorodithioate, phosphotriester, aminoalkylphosphotriester, H-phosphonate, methyl and other alkyl phosphonate including 3′-alkylene phosphonate, 5′-alkylene phosphonate and chiral phosphonate, phosphinate, phosphoramidate including 3′-amino phosphoramidate and aminoalkylphosphoramidate, thionophosphoramidate, thionoalkylphosphonate, thionoalkylphosphotriester, selenophosphate or boranophosphate.
A further preferred nucleotide analogue or equivalent of the invention comprises one or more sugar moieties that are mono- or disubstituted at the 2′, 3′ and/or 5′ position such as a —OH; —F; substituted or unsubstituted, linear or branched lower (C1-C10) alkyl, alkenyl, alkynyl, alkaryl, allyl, aryl, or aralkyl, that may be interrupted by one or more heteroatoms; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; O-, S-, or N-allyl; O-alkyl-O-alkyl, -methoxy, -aminopropoxy; -aminoxy; methoxyethoxy; -dimethylaminooxyethoxy; and -dimethylaminoethoxyethoxy. The sugar moiety can be a pyranose or derivative thereof, or a deoxypyranose or derivative thereof, preferably a ribose or a derivative thereof, or a deoxyribose or a derivative thereof. Such preferred derivatized sugar moieties comprise Locked Nucleic Acid (LNA), in which the 2′-carbon atom is linked to the 3′ or 4′ carbon atom of the sugar ring thereby forming a bicyclic sugar moiety. A preferred LNA comprises 2′-0,4′-C-ethylene-bridged nucleic acid (Morita et al. 2001. Nucleic Acid Res Supplement No. 1: 241-242). These substitutions render the nucleotide analogue or equivalent RNase H and nuclease resistant and increase the affinity for the target RNA.
It is understood by a skilled person that it is not necessary for all positions in an antisense oligonucleotide to be modified uniformly. In addition, more than one of the aforementioned analogues or equivalents may be incorporated in a single antisense oligonucleotide or even at a single position within an antisense oligonucleotide. In certain embodiments, an antisense oligonucleotide of the invention has at least two different types of analogues or equivalents.
A preferred antisense oligonucleotide according to the invention comprises a 2′-O alkyl phosphorothioate antisense oligonucleotide, such as 2′-O-methyl modified ribose (RNA), 2′-O-ethyl modified ribose, 2′-O-propyl modified ribose, and/or substituted derivatives of these modifications such as halogenated derivatives.
A most preferred antisense oligonucleotide according to the invention comprises of 2′-O-methyl phosphorothioate ribose.
A functional equivalent of a molecule of the invention may be defined as an oligonucleotide as defined herein wherein an activity of said functional equivalent is retained to at least some extent. Preferably, an activity of said functional equivalent is inducing exon 43, 46, 50, 51, 52, or 53 skipping and providing a functional dystrophin protein. Said activity of said functional equivalent is therefore preferably assessed by detection of exon 43, 46, 50, 51, 52, or 53 skipping and by quantifying the amount of functional dystrophin protein. A functional dystrophin is herein preferably defined as being a dystrophin able to bind actin and members of the DGC protein complex. The assessment of said activity of an oligonucleotide is preferably done by RT-PCR or by immunofluorescence or Western blot analyses. Said activity is preferably retained to at least some extent when it represents at least 50%, or at least 60%, or at least 70% or at least 80% or at least 90% or at least 95% or more of corresponding activity of said oligonucleotide the functional equivalent derives from. Throughout this application, when the word oligonucleotide is used it may be replaced by a functional equivalent thereof as defined herein.
It will be understood by a skilled person that distinct antisense oligonucleotides can be combined for efficiently skipping any of exon 43, exon 46, exon 50, exon 51, exon 52 and/or exon 53 of the human DMD pre-mRNA. It is encompassed by the present invention to use one, two, three, four, five or more oligonucleotides for skipping one of said exons (i.e. exon, 43, 46, 50, 51, 52, or 53). It is also encompassed to use at least two oligonucleotides for skipping at least two, of said exons. Preferably two of said exons are skipped. More preferably, these two exons are:
−43 and 51, or
−43 and 53, or
−50 and 51, or
−51 and 52, or
−52 and 53.
The skilled person will know which combination of exons is preferred to be skipped depending on the type, the number and the location of the mutation present in a DMD or BMD patient.
An antisense oligonucleotide can be linked to a moiety that enhances uptake of the antisense oligonucleotide in cells, preferably muscle cells. Examples of such moieties are cholesterols, carbohydrates, vitamins, biotin, lipids, phospholipids, cell-penetrating peptides including but not limited to antennapedia, TAT, transportan and positively charged amino acids such as oligoarginine, poly-arginine, oligolysine or polylysine, antigen-binding domains such as provided by an antibody, a Fab fragment of an antibody, or a single chain antigen binding domain such as a cameloid single domain antigen-binding domain.
A preferred antisense oligonucleotide comprises a peptide-linked PMO.
A preferred antisense oligonucleotide comprising one or more nucleotide analogs or equivalents of the invention modulates splicing in one or more muscle cells, including heart muscle cells, upon systemic delivery. In this respect, systemic delivery of an antisense oligonucleotide comprising a specific nucleotide analog or equivalent might result in targeting a subset of muscle cells, while an antisense oligonucleotide comprising a distinct nucleotide analog or equivalent might result in targeting of a different subset of muscle cells. Therefore, in one embodiment it is preferred to use a combination of antisense oligonucleotides comprising different nucleotide analogs or equivalents for inducing skipping of exon 43, 46, 50, 51, 52, or 53 of the human DMD pre-mRNA.
A cell can be provided with a molecule capable of interfering with essential sequences that result in highly efficient skipping of exon 43, exon 46, exon 50, exon 51, exon 52 or exon 53 of the human DMD pre-mRNA by plasmid-derived antisense oligonucleotide expression or viral expression provided by adenovirus- or adeno-associated virus-based vectors. In a preferred embodiment, there is provided a viral-based expression vector comprising an expression cassette that drives expression of a molecule as identified herein. Expression is preferably driven by a polymerase III promoter, such as a U1, a U6, or a U7 RNA promoter. A muscle or myogenic cell can be provided with a plasmid for antisense oligonucleotide expression by providing the plasmid in an aqueous solution. Alternatively, a plasmid can be provided by transfection using known transfection agentia such as, for example, LipofectAMINE™ 2000 (Invitrogen) or polyethyleneimine (PEI; ExGen500 (MBI Fermentas)), or derivatives thereof.
One preferred antisense oligonucleotide expression system is an adenovirus associated virus (AAV)-based vector. Single chain and double chain AAV-based vectors have been developed that can be used for prolonged expression of small antisense nucleotide sequences for highly efficient skipping of exon 43, 46, 50, 51, 52 or 53 of the DMD pre-mRNA.
A preferred AAV-based vector comprises an expression cassette that is driven by a polymerase III-promoter (Pol III). A preferred Pol III promoter is, for example, a U1, a U6, or a U7 RNA promoter.
The invention therefore also provides a viral-based vector, comprising a Pol III-promoter driven expression cassette for expression of one or more antisense sequences of the invention for inducing skipping of exon 43, exon 46, exon 50, exon 51, exon 52 or exon 53 of the human DMD pre-mRNA.
Pharmaceutical Composition
If required, a molecule or a vector expressing an antisense oligonucleotide of the invention can be incorporated into a pharmaceutically active mixture or composition by adding a pharmaceutically acceptable carrier.
Therefore, in a further aspect, the invention provides a composition, preferably a pharmaceutical composition comprising a molecule comprising an antisense oligonucleotide according to the invention, and/or a viral-based vector expressing the antisense sequence(s) according to the invention and a pharmaceutically acceptable carrier.
A preferred pharmaceutical composition comprises a molecule as defined herein and/or a vector as defined herein, and a pharmaceutical acceptable carrier or excipient, optionally combined with a molecule and/or a vector as defined herein which is able to induce skipping of exon 6, 7, 11, 17, 19, 21, 43, 44, 45, 50, 51, 52, 53, 55, 57, 59, 62, 63, 65, 66, 69, or 75 of the DMD pre-mRNA. Preferred molecules able to induce skipping of any of these exon are identified in any one of Tables 1 to 7.
Preferred excipients include excipients capable of forming complexes, vesicles and/or liposomes that deliver such a molecule as defined herein, preferably an oligonucleotide complexed or trapped in a vesicle or liposome through a cell membrane. Many of these excipients are known in the art. Suitable excipients comprise polyethylenimine and derivatives, or similar cationic polymers, including polypropyleneimine or polyethylenimine copolymers (PECs) and derivatives, ExGen 500, synthetic amphiphils (SAINT-18), Lipofectin™, DOTAP and/or viral capsid proteins that are capable of self assembly into particles that can deliver such molecule, preferably an oligonucleotide as defined herein to a cell, preferably a muscle cell. Such excipients have been shown to efficiently deliver (oligonucleotide such as antisense) nucleic acids to a wide variety of cultured cells, including muscle cells. Their high transfection potential is combined with an excepted low to moderate toxicity in terms of overall cell survival. The ease of structural modification can be used to allow further modifications and the analysis of their further (in vivo) nucleic acid transfer characteristics and toxicity.
Lipofectin represents an example of a liposomal transfection agent. It consists of two lipid components, a cationic lipid N-[1-(2,3 dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA) (cp. DOTAP which is the methylsulfate salt) and a neutral lipid dioleoylphosphatidylethanolamine (DOPE). The neutral component mediates the intracellular release. Another group of delivery systems are polymeric nanoparticles.
Polycations such like diethylaminoethylaminoethyl (DEAE)-dextran, which are well known as DNA transfection reagent can be combined with butylcyanoacrylate (PBCA) and hexylcyanoacrylate (PHCA) to formulate cationic nanoparticles that can deliver a molecule or a compound as defined herein, preferably an oligonucleotide across cell membranes into cells.
In addition to these common nanoparticle materials, the cationic peptide protamine offers an alternative approach to formulate a compound as defined herein, preferably an oligonucleotide as colloids. This colloidal nanoparticle system can form so called proticles, which can be prepared by a simple self-assembly process to package and mediate intracellular release of a compound as defined herein, preferably an oligonucleotide. The skilled person may select and adapt any of the above or other commercially available alternative excipients and delivery systems to package and deliver a compound as defined herein, preferably an oligonucleotide for use in the current invention to deliver said compound for the treatment of Duchenne Muscular Dystrophy or Becker Muscular Dystrophy in humans.
In addition, a compound as defined herein, preferably an oligonucleotide could be covalently or non-covalently linked to a targeting ligand specifically designed to facilitate the uptake in to the cell, cytoplasm and/or its nucleus. Such ligand could comprise (i) a compound (including but not limited to peptide(-like) structures) recognising cell, tissue or organ specific elements facilitating cellular uptake and/or (ii) a chemical compound able to facilitate the uptake in to cells and/or the intracellular release of an a compound as defined herein, preferably an oligonucleotide from vesicles, e.g. endosomes or lysosomes.
Therefore, in a preferred embodiment, a compound as defined herein, preferably an oligonucleotide are formulated in a medicament which is provided with at least an excipient and/or a targeting ligand for delivery and/or a delivery device of said compound to a cell and/or enhancing its intracellular delivery. Accordingly, the invention also encompasses a pharmaceutically acceptable composition comprising a compound as defined herein, preferably an oligonucleotide and further comprising at least one excipient and/or a targeting ligand for delivery and/or a delivery device of said compound to a cell and/or enhancing its intracellular delivery. It is to be understood that a molecule or compound or oligonucleotide may not be formulated in one single composition or preparation. Depending on their identity, the skilled person will know which type of formulation is the most appropriate for each compound.
In a preferred embodiment, an in vitro concentration of a molecule or an oligonucleotide as defined herein, which is ranged between 0.1 nM and 1 μM is used. More preferably, the concentration used is ranged between 0.3 to 400 nM, even more preferably between 1 to 200 nM. A molecule or an oligonucleotide as defined herein may be used at a dose which is ranged between 0.1 and 20 mg/kg, preferably 0.5 and 10 mg/kg. If several molecules or oligonucleotides are used, these concentrations may refer to the total concentration of oligonucleotides or the concentration of each oligonucleotide added. The ranges of concentration of oligonucleotide(s) as given above are preferred concentrations for in vitro or ex vivo uses. The skilled person will understand that depending on the oligonucleotide(s) used, the target cell to be treated, the gene target and its expression levels, the medium used and the transfection and incubation conditions, the concentration of oligonucleotide(s) used may further vary and may need to be optimised any further.
More preferably, a compound preferably an oligonucleotide to be used in the invention to prevent, treat DMD or BMD are synthetically produced and administered directly to a cell, a tissue, an organ and/or patients in formulated form in a pharmaceutically acceptable composition or preparation. The delivery of a pharmaceutical composition to the subject is preferably carried out by one or more parenteral injections, e.g. intravenous and/or subcutaneous and/or intramuscular and/or intrathecal and/or intraventricular administrations, preferably injections, at one or at multiple sites in the human body.
A preferred oligonucleotide as defined herein optionally comprising one or more nucleotide analogs or equivalents of the invention modulates splicing in one or more muscle cells, including heart muscle cells, upon systemic delivery. In this respect, systemic delivery of an oligonucleotide comprising a specific nucleotide analog or equivalent might result in targeting a subset of muscle cells, while an oligonucleotide comprising a distinct nucleotide analog or equivalent might result in targeting of a different subset of muscle cells.
In this respect, systemic delivery of an oligonucleotide comprising a specific nucleotide analog or equivalent might result in targeting a subset of muscle cells, while an oligonucleotide comprising a distinct nucleotide analog or equivalent might result in targeting a different subset of muscle cells. Therefore, in this embodiment, it is preferred to use a combination of oligonucleotides comprising different nucleotide analogs or equivalents for modulating splicing of the DMD mRNA in at least one type of muscle cells.
In a preferred embodiment, there is provided a molecule or a viral-based vector for use as a medicament, preferably for modulating splicing of the DMD pre-mRNA, more preferably for promoting or inducing skipping of any of exon 43, 46, 50-53 as identified herein.
Use
In yet a further aspect, the invention provides the use of an antisense oligonucleotide or molecule according to the invention, and/or a viral-based vector that expresses one or more antisense sequences according to the invention and/or a pharmaceutical composition, for modulating splicing of the DMD pre-mRNA. The splicing is preferably modulated in a human myogenic cell or muscle cell in vitro. More preferred is that splicing is modulated in a human muscle cell in vivo. Accordingly, the invention further relates to the use of the molecule as defined herein and/or the vector as defined herein and/or or the pharmaceutical composition as defined herein for modulating splicing of the DMD pre-mRNA or for the preparation of a medicament for the treatment of a DMD or BMD patient.
In this document and in its claims, the verb “to comprise” and its conjugations is used in its non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded. In addition the verb “to consist” may be replaced by “to consist essentially of” meaning that a molecule or a viral-based vector or a composition as defined herein may comprise additional component(s) than the ones specifically identified, said additional component(s) not altering the unique characteristic of the invention. In addition, reference to an element by the indefinite article “a” or “an” does not exclude the possibility that more than one of the element is present, unless the context clearly requires that there be one and only one of the elements. The indefinite article “a” or “an” thus usually means “at least one”. Each embodiment as identified herein may be combined together unless otherwise indicated. All patent and literature references cited in the present specification are hereby incorporated by reference in their entirety.
The following examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.
Materials and Methods
AON design was based on (partly) overlapping open secondary structures of the target exon RNA as predicted by the m-fold program, on (partly) overlapping putative SR-protein binding sites as predicted by the ESE-finder software. AONs were synthesized by Prosensa Therapeutics B.V. (Leiden, Netherlands), and contain 2′-O-methyl RNA and full-length phosphorothioate (PS) backbones.
Tissue Culturing, Transfection and RT-PCR Analysis
Myotube cultures derived from a healthy individual (“human control”) (examples 1, 3, and 4; exon 43, 50, 52 skipping) or a DMD patient carrying an exon 45 deletion (example 2; exon 46 skipping) were processed as described previously (Aartsma-Rus et al., Neuromuscul. Disord. 2002; 12: S71-77 and Hum Mol Genet 2003; 12(8): 907-14). For the screening of AONs, myotube cultures were transfected with 50 nM and 150 nM (example 2), 200 nM and 500 nM (example 4) or 500 nM only (examples 1 and 3) of each AON. Transfection reagent UNIFectylin (Prosensa Therapeutics BV, Netherlands) was used, with 2 μl UNIFectylin perm AON. Exon skipping efficiencies were determined by nested RT-PCR analysis using primers in the exons flanking the targeted exons (43, 46, 50, 51, 52, or 53). PCR fragments were isolated from agarose gels for sequence verification. For quantification, the PCR products were analyzed using the DNA 1000 LabChips Kit on the Agilent 2100 bioanalyzer (Agilent Technologies, USA).
Results
DMD Exon 43 Skipping.
A series of AONs targeting sequences within exon 43 were designed and transfected in healthy control myotube cultures. Subsequent RT-PCR and sequence analysis of isolated RNA demonstrated that almost all AONs targeting a continuous nucleotide stretch within exon 43 herein defined as SEQ ID NO 2, was indeed capable of inducing exon 43 skipping. PS237 (SEQ ID NO: 65) reproducibly induced highest levels of exon 43 skipping (up to 66%) at 500 nM, as shown in
DMD Exon 46 Skipping.
A series of AONs targeting sequences within exon 46 were designed and transfected in myotube cultures derived from a DMD patient carrying an exon 45 deletion in the DMD gene. For patients with such mutation antisense-induced exon 46 skipping would induce the synthesis of a novel, BMD-like dystrophin protein that may indeed alleviate one or more symptoms of the disease. Subsequent RT-PCR and sequence analysis of isolated RNA demonstrated that almost all AONs targeting a continuous nucleotide stretch within exon 46 herein defined as SEQ ID NO 3, was indeed capable of inducing exon 46 skipping, even at relatively low AON concentrations of 50 nM. PS182 (SEQ ID NO: 117) reproducibly induced highest levels of exon 46 skipping (up to 50% at 50 nM and 74% at 150 nM), as shown in
DMD Exon 50 Skipping.
A series of AONs targeting sequences within exon 50 were designed and transfected in healthy control myotube cultures. Subsequent RT-PCR and sequence analysis of isolated RNA demonstrated that almost all AONs targeting a continuous nucleotide stretch within exon 50 herein defined as SEQ ID NO 4, was indeed capable of inducing exon 50 skipping. PS248 (SEQ ID NO: 127) reproducibly induced highest levels of exon 50 skipping (up to 35% at 500 nM), as shown in
DMD Exon 51 Skipping.
A series of AONs targeting sequences within exon 51 were designed and transfected in healthy control myotube cultures. Subsequent RT-PCR and sequence analysis of isolated RNA demonstrated that almost all AONs targeting a continuous nucleotide stretch within exon 51 herein defined as SEQ ID NO 5, was indeed capable of inducing exon 51 skipping. The AON with SEQ ID NO 180 reproducibly induced highest levels of exon 51 skipping (not shown).
DMD Exon 52 Skipping.
A series of AONs targeting sequences within exon 52 were designed and transfected in healthy control myotube cultures. Subsequent RT-PCR and sequence analysis of isolated RNA demonstrated that almost all AONs targeting a continuous nucleotide stretch within exon 52 herein defined as SEQ ID NO 6, was indeed capable of inducing exon 52 skipping. PS236 (SEQ ID NO: 299) reproducibly induced highest levels of exon 52 skipping (up to 88% at 200 nM and 91% at 500 nM), as shown in
DMD Exon 53 Skipping.
A series of AONs targeting sequences within exon 53 were designed and transfected in healthy control myotube cultures. Subsequent RT-PCR and sequence analysis of isolated RNA demonstrated that almost all AONs targeting a continuous nucleotide stretch within exon 53 herein defined as SEQ ID NO 7, was indeed capable of inducing exon 53 skipping. The AON with SEQ ID NO 328 reproducibly induced highest levels of exon 53 skipping (not shown).
This application is a continuation of U.S. application Ser. No. 15/289,053 filed on Oct. 7, 2016 which is a continuation of U.S. application Ser. No. 14/631,686 filed on Feb. 25, 2015, now U.S. Pat. No. 9,499,818, issued Nov. 22, 2016, which is a continuation of U.S. application Ser. No. 13/094,571 filed Apr. 26, 2011, which is a continuation of International Application No. PCT/NL2009/050113, filed on Mar. 11, 2009, which is a continuation of PCT/NL2008/050673, filed on Oct. 27, 2008, the contents of each of which are herein incorporated by reference in their entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 5034506 | Summerton et al. | Jul 1991 | A |
| 5418139 | Campbell | May 1995 | A |
| 5541308 | Hogan et al. | Jul 1996 | A |
| 5593974 | Rosenberg et al. | Jan 1997 | A |
| 5608046 | Cook et al. | Mar 1997 | A |
| 5624803 | Noonberg et al. | Apr 1997 | A |
| 5627263 | Ruoslahti et al. | May 1997 | A |
| 5658764 | Pergolizzi et al. | Aug 1997 | A |
| 5741645 | Orr et al. | Apr 1998 | A |
| 5766847 | Jaeckle et al. | Jun 1998 | A |
| 5853995 | Lee | Dec 1998 | A |
| 5869252 | Bouma et al. | Feb 1999 | A |
| 5916808 | Kole et al. | Jun 1999 | A |
| 5962332 | Singer et al. | Oct 1999 | A |
| 5968909 | Agrawal et al. | Oct 1999 | A |
| 5976879 | Kole et al. | Nov 1999 | A |
| 6124100 | Jin | Sep 2000 | A |
| 6130207 | Dean et al. | Oct 2000 | A |
| 6133031 | Monia et al. | Oct 2000 | A |
| 6165786 | Bennett et al. | Dec 2000 | A |
| 6172208 | Cook | Jan 2001 | B1 |
| 6172216 | Bennett et al. | Jan 2001 | B1 |
| 6210892 | Bennett et al. | Apr 2001 | B1 |
| 6251589 | Tsuji et al. | Jun 2001 | B1 |
| 6280938 | Ranum et al. | Aug 2001 | B1 |
| 6300060 | Kantoff et al. | Oct 2001 | B1 |
| 6322978 | Kahn et al. | Nov 2001 | B1 |
| 6329501 | Smith et al. | Dec 2001 | B1 |
| 6355481 | Li et al. | Mar 2002 | B1 |
| 6355690 | Tsuji | Mar 2002 | B1 |
| 6369038 | Blumenfeld et al. | Apr 2002 | B1 |
| 6379698 | Leamon | Apr 2002 | B1 |
| 6399575 | Smith et al. | Jun 2002 | B1 |
| 6514755 | Ranum et al. | Feb 2003 | B1 |
| 6623927 | Brahmachari et al. | Sep 2003 | B1 |
| 6653466 | Matsuo | Nov 2003 | B2 |
| 6653467 | Matsuo et al. | Nov 2003 | B1 |
| 6670461 | Wengel et al. | Dec 2003 | B1 |
| 6727355 | Matsuo et al. | Apr 2004 | B2 |
| 6794192 | Parums et al. | Sep 2004 | B2 |
| 6875736 | Rana | Apr 2005 | B2 |
| 6902896 | Ranum et al. | Jun 2005 | B2 |
| 6982150 | Sheetz et al. | Jan 2006 | B2 |
| 7001994 | Zhu | Feb 2006 | B2 |
| 7034009 | Pavco et al. | Apr 2006 | B2 |
| 7118893 | Ranum et al. | Oct 2006 | B2 |
| 7189530 | Botstein et al. | Mar 2007 | B2 |
| 7202210 | Wolfman et al. | Apr 2007 | B2 |
| 7250404 | Felgner et al. | Jul 2007 | B2 |
| 7320965 | Sah et al. | Jan 2008 | B2 |
| 7355018 | Glass | Apr 2008 | B2 |
| 7405193 | Lodish et al. | Jul 2008 | B2 |
| 7442782 | Ranum et al. | Oct 2008 | B2 |
| 7514551 | Rabbani et al. | Apr 2009 | B2 |
| 7534879 | Van Deutekom et al. | May 2009 | B2 |
| 7589189 | Ichiro et al. | Sep 2009 | B2 |
| 7655785 | Bentwich | Feb 2010 | B1 |
| 7742782 | Kim et al. | Jun 2010 | B2 |
| 7771727 | Fuselier et al. | Aug 2010 | B2 |
| 7807816 | Wilson et al. | Oct 2010 | B2 |
| 7902160 | Matsuo et al. | Mar 2011 | B2 |
| 7960541 | Wilton et al. | Jun 2011 | B2 |
| 7973015 | Van Ommen et al. | Jul 2011 | B2 |
| 8084601 | Popplewell et al. | Dec 2011 | B2 |
| 8232384 | Wilton et al. | Jul 2012 | B2 |
| 8263760 | De Kimpe et al. | Sep 2012 | B2 |
| 8268962 | Heemskerk et al. | Sep 2012 | B2 |
| 8304398 | 'Thoen et al. | Nov 2012 | B2 |
| 8324371 | Popplewell et al. | Dec 2012 | B2 |
| 8361979 | Aartsma-Rus et al. | Jan 2013 | B2 |
| 8450474 | Wilton et al. | May 2013 | B2 |
| 8455634 | Wilton et al. | Jun 2013 | B2 |
| 8455635 | Wilton et al. | Jun 2013 | B2 |
| 8455636 | Wilton et al. | Jun 2013 | B2 |
| 8476423 | Wilton et al. | Jul 2013 | B2 |
| 8486907 | Wilton et al. | Jul 2013 | B2 |
| 8519097 | Heemskerk et al. | Aug 2013 | B2 |
| 8524880 | Wilton et al. | Sep 2013 | B2 |
| 8609065 | Kuik-Romeijn et al. | Dec 2013 | B2 |
| 8637483 | Wilton et al. | Jan 2014 | B2 |
| 8759507 | Van Deutekom et al. | Jun 2014 | B2 |
| 8802645 | Van Ommen et al. | Aug 2014 | B2 |
| 8865883 | Sazani et al. | Oct 2014 | B2 |
| 9057066 | Hung et al. | Jun 2015 | B2 |
| 9079934 | Watanabe et al. | Jul 2015 | B2 |
| 9139828 | Platenburg et al. | Sep 2015 | B2 |
| 9234198 | Sazani | Jan 2016 | B1 |
| 9243026 | Matsuo et al. | Jan 2016 | B2 |
| 9243245 | De Kimpe et al. | Jan 2016 | B2 |
| 9499818 | Van Deutekom et al. | Nov 2016 | B2 |
| 9528109 | De Kimpe et al. | Dec 2016 | B2 |
| 20010056077 | Matsuo | Dec 2001 | A1 |
| 20020049173 | Bennett et al. | Apr 2002 | A1 |
| 20020055481 | Matsuo et al. | May 2002 | A1 |
| 20020109476 | Kim | Aug 2002 | A1 |
| 20020115824 | Engler et al. | Aug 2002 | A1 |
| 20020165150 | Ben-Sasson | Nov 2002 | A1 |
| 20030045488 | Brown et al. | Mar 2003 | A1 |
| 20030073215 | Baker et al. | Apr 2003 | A1 |
| 20030082763 | Baker et al. | May 2003 | A1 |
| 20030082766 | Baker et al. | May 2003 | A1 |
| 20030109476 | Kmiec et al. | Jun 2003 | A1 |
| 20030124523 | Asselbergs et al. | Jul 2003 | A1 |
| 20030130224 | Monahan et al. | Jul 2003 | A1 |
| 20030134790 | Genfeld | Jul 2003 | A1 |
| 20030235845 | Van Ommen et al. | Dec 2003 | A1 |
| 20030236214 | Wolff et al. | Dec 2003 | A1 |
| 20040101852 | Bennett et al. | May 2004 | A1 |
| 20040132684 | Sampath et al. | Jul 2004 | A1 |
| 20040219565 | Kauppinen et al. | Nov 2004 | A1 |
| 20040226056 | Roch et al. | Nov 2004 | A1 |
| 20050048495 | Baker et al. | Mar 2005 | A1 |
| 20050096284 | McSwiggen | May 2005 | A1 |
| 20050222009 | Lamensdorf et al. | Oct 2005 | A1 |
| 20050246794 | Khvorova et al. | Nov 2005 | A1 |
| 20050277133 | McSwiggen | Dec 2005 | A1 |
| 20050288246 | Iversen et al. | Dec 2005 | A1 |
| 20060003322 | Bentwich | Jan 2006 | A1 |
| 20060024715 | Liu et al. | Feb 2006 | A1 |
| 20060074034 | Collins et al. | Apr 2006 | A1 |
| 20060099612 | Nakao et al. | May 2006 | A1 |
| 20060099616 | Van Ommen et al. | May 2006 | A1 |
| 20060147952 | Van Ommen et al. | Jul 2006 | A1 |
| 20060148740 | Platenburg | Jul 2006 | A1 |
| 20060160121 | Mounts et al. | Jul 2006 | A1 |
| 20070021360 | Nyce et al. | Jan 2007 | A1 |
| 20070082861 | Matsuo et al. | Apr 2007 | A1 |
| 20070134655 | Bentwich | Jun 2007 | A1 |
| 20070141628 | Cunningham et al. | Jun 2007 | A1 |
| 20070275914 | Manoharan et al. | Nov 2007 | A1 |
| 20070292408 | Singh et al. | Dec 2007 | A1 |
| 20070299027 | Hung et al. | Dec 2007 | A1 |
| 20080015158 | Ichiro et al. | Jan 2008 | A1 |
| 20080015185 | Ahmed et al. | Jan 2008 | A1 |
| 20080039418 | Freier | Feb 2008 | A1 |
| 20080113351 | Naito et al. | May 2008 | A1 |
| 20080200409 | Wilson et al. | Aug 2008 | A1 |
| 20080207538 | Lawrence et al. | Aug 2008 | A1 |
| 20080209581 | Van Ommen et al. | Aug 2008 | A1 |
| 20080249294 | Haeberli et al. | Oct 2008 | A1 |
| 20090092981 | Swayze et al. | Apr 2009 | A1 |
| 20090099066 | Moulton et al. | Apr 2009 | A1 |
| 20090228998 | Van Ommen et al. | Sep 2009 | A1 |
| 20090312532 | Van Deutekom | Dec 2009 | A1 |
| 20100081627 | Sampath et al. | Apr 2010 | A1 |
| 20100099750 | McSwiggen et al. | Apr 2010 | A1 |
| 20100130591 | Sazani et al. | May 2010 | A1 |
| 20100168212 | Popplewell et al. | Jul 2010 | A1 |
| 20100184833 | De Kimpe et al. | Jul 2010 | A1 |
| 20100216238 | Baker et al. | Aug 2010 | A1 |
| 20100248239 | Highsmith, Jr. et al. | Sep 2010 | A1 |
| 20100286235 | Renzi et al. | Nov 2010 | A1 |
| 20110015253 | Wilton et al. | Jan 2011 | A1 |
| 20110015258 | Wilton et al. | Jan 2011 | A1 |
| 20110054005 | Naito et al. | Mar 2011 | A1 |
| 20110166081 | Campbell et al. | Jul 2011 | A1 |
| 20110184050 | De Kimpe et al. | Jul 2011 | A1 |
| 20110263682 | De Kimpe et al. | Oct 2011 | A1 |
| 20110263686 | Wilton et al. | Oct 2011 | A1 |
| 20110294753 | De Kimpe et al. | Dec 2011 | A1 |
| 20120022134 | De Kimpe et al. | Jan 2012 | A1 |
| 20120022144 | Wilton et al. | Jan 2012 | A1 |
| 20120022145 | Wilton et al. | Jan 2012 | A1 |
| 20120029057 | Wilton et al. | Feb 2012 | A1 |
| 20120029058 | Wilton et al. | Feb 2012 | A1 |
| 20120029059 | Wilton et al. | Feb 2012 | A1 |
| 20120029060 | Wilton et al. | Feb 2012 | A1 |
| 20120041050 | Wilton et al. | Feb 2012 | A1 |
| 20120046342 | Van Deutekom et al. | Feb 2012 | A1 |
| 20120046348 | Vaillant et al. | Feb 2012 | A1 |
| 20120108652 | Popplewell et al. | May 2012 | A1 |
| 20120122801 | Platenburg | May 2012 | A1 |
| 20120202752 | Lu | Aug 2012 | A1 |
| 20130072671 | Van Deutekom | Mar 2013 | A1 |
| 20130116310 | Wilton et al. | May 2013 | A1 |
| 20130211062 | Watanabe et al. | Aug 2013 | A1 |
| 20130217755 | Wilton et al. | Aug 2013 | A1 |
| 20130253033 | Wilton et al. | Sep 2013 | A1 |
| 20130253180 | Wilton et al. | Sep 2013 | A1 |
| 20130274313 | Wilton et al. | Oct 2013 | A1 |
| 20130302806 | Van Deutekom | Nov 2013 | A1 |
| 20130331438 | Wilton et al. | Dec 2013 | A1 |
| 20140045763 | Aguilera Diez et al. | Feb 2014 | A1 |
| 20140113955 | De Kimpe et al. | Apr 2014 | A1 |
| 20140128592 | De Kimpe et al. | May 2014 | A1 |
| 20140213635 | Van Deutekom | Jul 2014 | A1 |
| 20140221458 | De Kimpe et al. | Aug 2014 | A1 |
| 20140275212 | Van Deutekom | Sep 2014 | A1 |
| 20140298496 | Krainer et al. | Oct 2014 | A1 |
| 20140343266 | Watanabe et al. | Nov 2014 | A1 |
| 20140350076 | Van Deutekom | Nov 2014 | A1 |
| 20140357698 | Van Deutekom et al. | Dec 2014 | A1 |
| 20140357855 | Van Deutekom et al. | Dec 2014 | A1 |
| 20140378527 | Van Deutekom et al. | Dec 2014 | A1 |
| 20150045413 | De Visser et al. | Feb 2015 | A1 |
| 20150080563 | Van Deutekom et al. | Mar 2015 | A2 |
| 20150148404 | De Visser et al. | May 2015 | A1 |
| 20150191725 | Van Deutekom | Jul 2015 | A1 |
| 20150203849 | Van Deutekom et al. | Jul 2015 | A1 |
| 20150218559 | Van Deutekom et al. | Aug 2015 | A1 |
| 20150322434 | Van Deutekom et al. | Nov 2015 | A1 |
| 20150361424 | Van Deutekom | Dec 2015 | A1 |
| 20160040161 | Packard et al. | Feb 2016 | A1 |
| 20160053254 | De Kimpe et al. | Feb 2016 | A1 |
| 20160053262 | Platenburg et al. | Feb 2016 | A1 |
| 20160168570 | Van Deutekom et al. | Jun 2016 | A1 |
| 20160194636 | Van Deutekom et al. | Jul 2016 | A1 |
| 20160251658 | Van Deutekom et al. | Sep 2016 | A1 |
| 20160264967 | Van Deutekom et al. | Sep 2016 | A1 |
| 20160304864 | De Kimpe et al. | Oct 2016 | A1 |
| 20160355810 | Van Deutekom | Dec 2016 | A1 |
| 20170029818 | De Visser et al. | Feb 2017 | A1 |
| 20170029820 | Aguilera Diez et al. | Feb 2017 | A1 |
| 20170044534 | Van Deutekom | Feb 2017 | A1 |
| 20170107512 | De Kimpe et al. | Apr 2017 | A1 |
| Number | Date | Country |
|---|---|---|
| 2319149 | Oct 2001 | CA |
| 2526893 | Nov 2004 | CA |
| 101501193 | Aug 2009 | CN |
| 0558697 | Sep 1993 | EP |
| 0614977 | Sep 1994 | EP |
| 0 438 512 | Dec 1997 | EP |
| 0438512 | Dec 1997 | EP |
| 0850300 | Jul 1998 | EP |
| 1015628 | Jul 2000 | EP |
| 1054058 | Nov 2000 | EP |
| 1133993 | Sep 2001 | EP |
| 1160318 | Dec 2001 | EP |
| 1191097 | Mar 2002 | EP |
| 1191098 | Mar 2002 | EP |
| 1380644 | Jan 2004 | EP |
| 1487493 | Dec 2004 | EP |
| 1495769 | Jan 2005 | EP |
| 1501931 | Feb 2005 | EP |
| 1544297 | Jun 2005 | EP |
| 1567667 | Aug 2005 | EP |
| 1568769 | Aug 2005 | EP |
| 1619249 | Jan 2006 | EP |
| 1 191 098 | Jun 2006 | EP |
| 1857548 | Nov 2007 | EP |
| 2119783 | Nov 2009 | EP |
| 2135948 | Dec 2009 | EP |
| 2344637 | Dec 2014 | EP |
| 20030035047 | May 2003 | KR |
| WO 1993001286 | Jan 1993 | WO |
| WO 1994028175 | Dec 1994 | WO |
| 9516718 | Jun 1995 | WO |
| WO 1995016718 | Jun 1995 | WO |
| WO 1995021184 | Aug 1995 | WO |
| WO 1995030774 | Nov 1995 | WO |
| WO 1997012899 | Apr 1997 | WO |
| WO 1997030067 | Aug 1997 | WO |
| WO 1998018920 | May 1998 | WO |
| WO 1998 43993 | Oct 1998 | WO |
| WO 1998049345 | Nov 1998 | WO |
| WO 1998053804 | Dec 1998 | WO |
| WO 1999016871 | Apr 1999 | WO |
| WO 1999055857 | Nov 1999 | WO |
| WO 1999063975 | Dec 1999 | WO |
| WO 2000024885 | May 2000 | WO |
| WO 2000076554 | Dec 2000 | WO |
| WO 2001016312 | Mar 2001 | WO |
| 0132832 | May 2001 | WO |
| WO 2001059102 | Aug 2001 | WO |
| WO 2001079283 | Oct 2001 | WO |
| WO 2001083503 | Nov 2001 | WO |
| WO 2001083695 | Nov 2001 | WO |
| WO 2002002406 | Jan 2002 | WO |
| WO 2002024906 | Mar 2002 | WO |
| WO 2002026812 | Apr 2002 | WO |
| WO 2002029006 | Apr 2002 | WO |
| WO 2002029056 | Apr 2002 | WO |
| WO 2003002739 | Jan 2003 | WO |
| WO 2003004511 | Jan 2003 | WO |
| WO 2003013437 | Feb 2003 | WO |
| WO 2003014145 | Feb 2003 | WO |
| WO 2003037172 | May 2003 | WO |
| 03062258 | Jul 2003 | WO |
| WO 2003062258 | Jul 2003 | WO |
| WO 2003095647 | Nov 2003 | WO |
| WO 2004011060 | Feb 2004 | WO |
| WO 2004015106 | Feb 2004 | WO |
| WO 2004016787 | Feb 2004 | WO |
| WO 2004037854 | May 2004 | WO |
| WO 2004047741 | Jun 2004 | WO |
| WO 2004048570 | Jun 2004 | WO |
| WO 2004083432 | Sep 2004 | WO |
| WO 2004083446 | Sep 2004 | WO |
| WO 2004101787 | Nov 2004 | WO |
| WO 2004108157 | Dec 2004 | WO |
| 2005021727 | Mar 2005 | WO |
| WO 2005019453 | Mar 2005 | WO |
| WO 2005023836 | Mar 2005 | WO |
| 2005035550 | Apr 2005 | WO |
| WO 2005035550 | Apr 2005 | WO |
| WO 2005085476 | Sep 2005 | WO |
| WO 2005086768 | Sep 2005 | WO |
| WO 2005105995 | Nov 2005 | WO |
| WO 2005115439 | Dec 2005 | WO |
| WO 2005115479 | Dec 2005 | WO |
| WO 2005116204 | Dec 2005 | WO |
| WO 2006000057 | Jan 2006 | WO |
| WO 2006007910 | Jan 2006 | WO |
| WO 2006017522 | Feb 2006 | WO |
| WO 2006031267 | Mar 2006 | WO |
| WO 2006054262 | May 2006 | WO |
| WO 2006083800 | Aug 2006 | WO |
| WO 2006108052 | Oct 2006 | WO |
| WO 2006112705 | Oct 2006 | WO |
| WO 2006121277 | Nov 2006 | WO |
| WO 2006121960 | Nov 2006 | WO |
| WO 2007002904 | Jan 2007 | WO |
| WO 2007004979 | Jan 2007 | WO |
| 2007018563 | Feb 2007 | WO |
| WO 2007044362 | Apr 2007 | WO |
| WO 2007089584 | Aug 2007 | WO |
| WO 2007089611 | Aug 2007 | WO |
| WO 2007123402 | Nov 2007 | WO |
| WO 2007135105 | Nov 2007 | WO |
| WO 2008011170 | Jan 2008 | WO |
| WO 2008018795 | Feb 2008 | WO |
| WO 2008021136 | Feb 2008 | WO |
| WO 2008039418 | Apr 2008 | WO |
| WO 2008043561 | Apr 2008 | WO |
| WO 2008103060 | Aug 2008 | WO |
| WO 2008103755 | Aug 2008 | WO |
| WO 2009005793 | Jan 2009 | WO |
| WO 2009008727 | Jan 2009 | WO |
| WO 2009015384 | Jan 2009 | WO |
| WO 2009054725 | Apr 2009 | WO |
| WO 2009099326 | Aug 2009 | WO |
| WO 2009101399 | Aug 2009 | WO |
| WO 2009120887 | Oct 2009 | WO |
| WO 2009135322 | Nov 2009 | WO |
| WO 2009139630 | Nov 2009 | WO |
| WO 2009144481 | Dec 2009 | WO |
| WO 2009151600 | Dec 2009 | WO |
| WO 2010001088 | Jan 2010 | WO |
| WO 2010006237 | Jan 2010 | WO |
| WO 2010014592 | Feb 2010 | WO |
| WO 2010044894 | Apr 2010 | WO |
| WO 2010048586 | Apr 2010 | WO |
| WO 2010050802 | May 2010 | WO |
| WO 2010110835 | Sep 2010 | WO |
| WO 2010115993 | Oct 2010 | WO |
| WO 2010123369 | Oct 2010 | WO |
| WO 2010144485 | Dec 2010 | WO |
| WO 2011032045 | Mar 2011 | WO |
| WO 2011057350 | May 2011 | WO |
| WO 2011078797 | Jun 2011 | WO |
| WO 2011097614 | Aug 2011 | WO |
| WO 2011097641 | Aug 2011 | WO |
| WO 2012012443 | Jan 2012 | WO |
| WO 2012021985 | Feb 2012 | WO |
| WO 2012029986 | Mar 2012 | WO |
| WO 2012109395 | Aug 2012 | WO |
| WO 2012150960 | Nov 2012 | WO |
| WO 2013082548 | Jun 2013 | WO |
| WO 2013082578 | Jun 2013 | WO |
| WO 2013100190 | Jul 2013 | WO |
| WO 2013120003 | Aug 2013 | WO |
| WO 2013170385 | Nov 2013 | WO |
| Entry |
|---|
| Aartsma-Rus, A., et al., “Antisense Mediated Exon Skipping; A Versatile Tool with Therapeutic and Research Applications,” RNA, vol. 13 (10), pp. 1609-1624, 2007. |
| Aartsma-Rus, A., et al., “Antisense-lnduced Exon Skipping for Duplications in Duchenne Muscular Dystrophy,” BMC Medical Genetics, vol. 8 (43), 9 pages, 2007. |
| Aartsma-Rus, A., et al., “Antisense-lnduced Multiexon Skipping for Duchenne Muscular Dystrophy Makes More Sense,” American Journal of Human Genetics, vol. 74, pp. 83-92, 2004. |
| Aartsma-Rus, A., et al., “Comparative Analysis of Antisense Oligonucleotide Analogs for Targeted DMD Exon 46 Skipping in Muscle Cells,” Gene Therapy, vol. 11 (18), pp. 1391-1398, 2004. |
| Aartsma-Rus, A., et al., “Exonic Sequences Provide Better Targets for Antisense Oligonucleotides Than Splice Site Sequences in the Modulation of Duchenne Muscular Dystrophy Splicing,” Oligonucleotides, vol. 20 (2), pp. 69-77, 2010. |
| Aartsma-Rus, A., et al., “Exploring the Frontiers of Therapeutic Exon Skipping for Duchenne Muscular Dystrophy by Double Targeting within One or Multiple Exons,” Molecular Therapy, vol. 14 (3), pp. 401-407, Sep. 2006. |
| Aartsma-Rus, A., et al., “Functional Analysis of 114 Exon-Internal AONs for Targeted DMD Exon Indication for Steric Hindrance of SR Protein Binding Sites,” Oligonucleotides, vol. 15, pp. 284-297, 2005. |
| Aartsma-Rus, A., et al., “Guidelines for Antisense Oligonucleotide Design and Insight Into Splice-Modulating Mechanisms,” Molecular Therapy, vol. 17 (3), pp. 548-553, Mar. 2009. |
| Aartsma-Rus, A., et al., “Targeted Exon Skipping as a Potential Gene Correction Therapy for Duchenne Muscular Dystrophy,” Neuromuscular Disorders, vol. 12, pp. S71-S77, 2002. |
| Aartsma-Rus, A., et al., “Theoretic Applicability of Antisense-Mediated Exon Skipping for Duchenne Muscular Dystrophy Mutations,” Human Mutation, vol. 30 (3), pp. 293-299, 2009. |
| Aartsma-Rus, A., et al., “Therapeutic Antisense-lnduced Exon Skipping in Cultured Muscle Cells from Six Different DMD Patients,” Human Molecular Genetics, vol. 12 (8), pp. 907-914, 2003. |
| Aartsma-Rus, A., et al., “Therapeutic Modulation of DMD Splicing by Blocking Exonic Splicing Enhancer Sites with Antisense Oligonucleotides,” Annals of the New York Academy of Sciences, vol. 1082, pp. 74-76, 2006. |
| Abbs, S., et al., “A Convenient Multiplex PCR System for the Detection of Dystrophin Gene Deletions: A Comparative Analysis with cDNA Hybridisation Shows Mistypings by Both Methods,” Journal of Medical Genetics, vol. 28, pp. 304-311, 1991. |
| Academisch Ziekenhuis Leiden, “Comparative analysis of AONs for inducing the skipping of exon 45 from the dystrophin gene in human control muscle cells,” 2 pages, Oct. 23, 2014. |
| Academisch Ziekenhuis Leiden, “Sequences of Exon 53, Putative SES Fragments and Oligonucleotides,” p. 1, Dec. 5, 2001. |
| Academisch Ziekenhuis Leiden, Academisch Ziekenhuis Leiden v. University of Western Australia, University of Western Australia v. Academisch Ziekenhuis Leiden, “Academisch Ziekenhuis Leiden's Response to Motion of University of Western Australia to Designate as Companion Cases to Extend the Briefing Schedules,” 6 pages, Nov. 18, 2016 [Interference Nos. 106,007, 106,008, 106,013]. |
| Academisch Ziekenhuis Leiden, Letter in Response to Article 94(3) EPC relating to EP2594641, 7 pages, Oct. 23, 2014. |
| Academisch Ziekenhuis Leiden, Patentee's letter to European Patent Office in the examination of EP 2602322, 4 pages, Dec. 9, 2013. |
| Academisch Ziekenhuis Leiden, Patentee's Response to Office Action to European Patent Office in the examination of EP 2602322, 6 pages, Oct. 21, 2014. |
| Academisch Ziekenhuis Leiden, Reply Brief of Appellant Academisch Ziekenhuis Leiden, US Court of Appeals for the Federal Circuit, Case: 16-2262, 40 pages, Apr. 25, 2017. |
| Academisch Ziekenhuis Leiden, Request for an Opinion under Section 74(A) in relation to Patent No. EP (UK) 1619249B, 33 pages, Apr. 20, 2009. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), Academisch Ziekenhuis Leiden List of Exhibits (as of Apr. 3, 2015) 18 pages, filed Apr. 3, 2015 [Patent Interference No. 106,007 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), Academisch Ziekenhuis Leiden's List of Proposed Motions, 6 pages, Sep. 10, 2014 [Patent Interference No. 106,007 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), Academisch Ziekenhuis Leiden's Opposition 4 (to Not Exclude Evidence), 22 pages, May 5, 2015 [Patent Interference No. 106,007 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), Academisch Ziekenhuis Leiden Reply 2 (to Deny the Benefit of AU 2004903474), 11 pages, filed Apr. 3, 2015 [Patent Interference No. 106,007 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), Academisch Ziekenhuis Leiden Reply 3 (for Judgment of Unpatentability based on Myriad), 12 pages, Apr. 3, 2015, [Patent Interference No. 106,007 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), Academisch Ziekenhuis Leiden Reply 4 (in Support of Responsive Motion 4 to Add Two New Claims), 17 pages, Apr. 3, 2015 [Patent Interference No. 106,007 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), Academisch Ziekenhuis Leiden Request for Oral Argument, 3 pages, Apr. 10, 2015 [Patent Interference No. 106,007 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), Academisch Ziekenhuis Leiden Responsive Motion 4 (to Add Two New Claims), 65 pages, filed Dec. 23, 2014 [Patent Interference No. 106,007 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), Academisch Ziekenhuis Leiden's Substantive Motion 1 (For Judgment that UWA Claims are Un patentable Under 35 U.S.C. §§ 102 and 103) 69 pages, Nov. 18, 2014 [Patent Interference No. 106,007 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), Academisch Ziekenhuis Leiden Substantive Motion 2 (to Deny UWA the Benefit of AU 2004903474), 23 pages, Nov. 18, 2014 [Patent Interference No. 106,007 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), Academisch Ziekenhuis Leiden's Substantive Motion 3 (For Judgment of Unpatentability based on Myriad), 19 pages, Nov. 18, 2014 [Patent Interference No. 106,007 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), Academisch Ziekenhuis Leiden List of Exhibits (as of Feb. 17, 2015), 18 pages, Feb. 17, 2015 [Patent Interference No. 106,007 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), Academisch Ziekenhuis Leiden's List of Exhibits (as of May 5, 2015) 18 pages, filed May 5, 2015 [Patent Interference No. 106,007 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), Academisch Ziekenhuis Leiden Opposition 1 (35 U.S. C. § 112(a)), 93 pages, Feb. 17, 2015 [Patent Interference No. 106,007 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), Academisch Ziekenhuis Leiden Opposition 2 (Indefiniteness), 31 pages, Feb. 17, 2015 [Patent Interference No. 106,007 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), Academisch Ziekenhuis Leiden Opposition 3 (Standing Order ¶ 203.1 and 37 C.F.R. § 41.202(a) and (e)), 20 pages, Feb. 17, 2015 [Patent Interference No. 106,007 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11 /233,495) and University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), Declaration of Judith Van Deutekom, 45 pages, Feb. 17, 2015 [Patent Interference Nos. 106,007 and 106,008 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. No. 8,486,907) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 14/198,992), Academisch Ziekenhuis Leiden List of Exhibits (as of Feb. 17, 2015) 3 pages, Feb. 17, 2015 [Patent Interference No. 106,013 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. No. 8,486,907) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 14/198,992), Academisch Ziekenhuis Leiden Opposition 1 (Standing Order ¶ 203.1 and 37 C.F.R. § 41.202 (a) and (e)) 20 pages, Feb. 17, 2015 [Patent Interference No. 106,013 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), Academisch Ziekenhuis Leiden Reply 1 (for Judgment that UWA's Claims are Un patentable Under 35 U.S.C. §§ 102 and 103), 17 pages, Apr. 3, 2015 [Patent Interference No. 106,007 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), Academisch Ziekenhuis Leiden List of Exhibits (as of Apr. 3, 2015), 18 pages, Apr. 3, 2015 [Patent Interference No. 106,008 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210) Academisch Ziekenhuis Leiden List of Exhibits (as of Feb. 17, 2015), 18 pages, Feb. 17, 2015 [Patent Interference No. 106,008 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), Academisch Ziekenhuis Leiden Opposition 1 (35 U.S.C. § 112(a)), 83 pages, Feb. 17, 2015 [Patent Interference No. 106,008 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), Academisch Ziekenhuis Leiden Opposition 2 (Indefiniteness), 32 pages, Feb. 17, 2015 [Patent Interference No. 106,008 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), Academisch Ziekenhuis Leiden Opposition 3 (35 U.S.C. § 135(b)), 44 pages, Feb. 17, 2015 [Patent Interference No. 106,008 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), Academisch Ziekenhuis Leiden Reply 1 (for Judgment that UWA's Claims are Un patentable Under 35 U.S.C. §§ 102 and 103), 17 pages, filed Apr. 3, 2015 [Patent Interference No. 106,008 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), Academisch Ziekenhuis Leiden Reply 2 (to Deny the Benefit of AU 2004903474), 12 pages, Apr. 3, 2015 [Patent Interference No. 106,008 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), Academisch Ziekenhuis Leiden Reply 3 (for Judgment of Unpatentability based on Myriad), 13 pages, Apr. 3, 2015 [Patent Interference No. 106,008 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), Academisch Ziekenhuis Leiden Reply 4 (in Support of Responsive Motion 4 to Add Two New Claims), 17 pages, filed Apr. 3, 2015 [Patent Interference No. 106,008 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), Academisch Ziekenhuis Leiden Request for Oral Argument, 3 pages, Apr. 10, 2015 [Patent Interference No. 106,008 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), Academisch Ziekenhuis Leiden Responsive Motion 4 (to Add Two New Claims), 57 pages, Dec. 23, 2014 [Patent Interference No. 106,008 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), Second Declaration of Erik Sontheimer, Ph.D., 44 pages, Dec. 23, 2014 [Patent Interference No. 106,008 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. Nos. 7,960,541, 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), Academisch Ziekenhuis Leiden's Substantive Motion 2 (To Deny UWA the Benefit of AU2004903474, 24 pages, filed Nov. 18, 2014 [Patent Interference No. 106,008 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,21 0), Academisch Ziekenhuis Leiden's List of Exhibits (as of May 5, 2015), 18 pages, filed May 5, 2015 [Patent Interference No. 106,008 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), Academisch Ziekenhuis Leiden's Opposition 4 (To Not Exclude Evidence), 21 pages, filed May 5, 2015 [Patent Interference No. 106,008 (RES). |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. Nos. 7,960,541, and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), Academisch Ziekenhuis Leiden Substantive Motion 1 (for Judgment that UWA's Claims are Unpatentable Under 35 U.S.C. §§ 102 and 103), 69 pages, filed Nov. 18, 2014 [Patent Interference No. 106,008 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. Nos. 7,960,541 and7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), Academisch Ziekenhuis Leiden's Substantive Motion 2 (To Deny UWA the Benefit of AU2004903474, 24 pages, Nov. 18, 2014 [Patent Interference No. 106,008 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia (U.S. Pat. Nos. 7,960,541 and7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), Academisch Ziekenhuis Leiden Substantive Motion 3 (For Judgment of Unpatentability Based on Myriad), 20 pages, Nov. 18, 2014 [Patent Interference No. 106,008 (RES)]. |
| Academisch Ziekenhuis Leiden, University of Western Australia v. Academisch Ziekenhuis Leiden, “Principal Brief of Appellee Academisch Ziekenhuis Leiden,” 69 pages, filed Mar. 28, 2017 [Interference No. 106,013]. |
| Academisch Ziekenhuis Leiden, University ofWestem Australia (U.S. Pat. Nos. 7,960,541, 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), Academisch Ziekenhuis Leiden's List of Proposed Motions, 8 pages, filed Sep. 10, 2014 [Patent Interference No. 106,008 (RES)]. |
| Agrawal, S., et al., “Antisense therapeutics: is it as simple as complementary base recognition?,” Molecular Medicine Today, vol. 6, pp. 72-81, Feb. 2000. |
| Alter, J., et al., “Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology,” Nature Medicine, 12(2), pp. 175-177, Feb. 2006. |
| Amalfitano, A., et al., “Dystrophin Gene, protein and cell biology: Structure and mutation of the dystrophin gene,” Cambridge University Press, pp. 1-28, 1997. |
| Anderson, J., et al., “Correlated NOS-Iμ and myf5 expression by satellite cells in mdx mouse muscle regeneration during NOS manipulation and deflazacort treatment,” Neuromuscular Disorders, vol. 13(5), pp. 388-396, Jun. 2003. |
| Anonymous, Third Party's Statement, Japanese Application No. 2002-529499, dated Oct. 29, 2010, 28 pages (English Translation attached). |
| Arap, W., et al., “Steps toward mapping the human vasculature by phage display,” Nature Medicine, vol. 8, No. 2, pp. 121-127, Feb. 2002. |
| Arechavala-Gomeza, V., et al., “Comparative Analysis of Antisense Oligonucleotide Sequences for Targeted Skipping of Exon 51 During Dystrophin Pre-mRNA Splicing in Human Muscle,” Human Gene Therapy, vol. 18 (9), pp. 798-810, 2007. |
| Aronin, N., “Expanded CAG Repeats in the Crosshairs,” Nature Biotechnology, May 2009, vol. 27 (5), pp. 451-452. |
| Arruda, V.R., “The Role of lmmunosuppression in Gene- and Cell-Based Treatments for Duchenne Muscular Dystrophy,” Molecular Therapy, vol. 15, No. 6, pp. 1040-1041, Jun. 2007. |
| Arzumanov, A., et al., “Inhibition of HIV-1 Tat-Dependent Trans Activation by Steric Block Chimeric 2′-O-Methyl/LNA Oligoribonucleotides,” Biochemistry, 2001, vol. 40 (48), pp. 14645-14654. |
| Atdbio, Ltd., “DNA Duplex Stability,” httg://www.atdbio.com/content/53/DNA-duglex-stability, 10 pages, 2008. |
| Austin, R.C., et al., “Cloning and Characterization of Alternatively Spliced lsoforms of Dp71,” Human Molecular Genetics, 1995, vol. 4 (9), pp. 1475-1483. |
| Austin, R.C., et al., “Expression and Synthesis of Alternatively Spliced Variants of Dp71 in Adult Human Brain,” Neuromuscular Disorders, 2000, vol. 10 (3), pp. 187-193. |
| Australian Government, IP Australia, Office Action for Australian Patent Application No. 2009240879, 3 pages, dated Jun. 22, 2011. |
| Avi Biopharma, Inc., “Grounds of Appeal” filed in the opposition proceeding of EP 1619249, dated Aug. 23, 2013, 41 pages. |
| Avi Biopharma, Inc., Notice of Opposition filed against EP1619249, 47 pages, Jun. 23, 2009. |
| Avi Biopharma, Inc., Reply of the Opponent to the Grounds of Appeal, dated Jan. 8, 2014, 31 pages. |
| Avi Biopharma, Inc., Request for UK IPO Opinion (Section 74A & Rule 93)—EP(UK) 1619249, 24 pages, dated Mar. 9, 2009. |
| Axelrod et al., “Intestinal Transport of Gentamicin with a Novel, Glycosteroid Drug Transport Agent,” Pharmaceutical Research, vol. 15, No. 12, pp. 1876-1881, 1998. |
| Barabino, S.M., et al., “Antisense Probes Targeted to an Internal Domain in U2 snRNP Specifically Inhibit the Second Step of Pre-mRNA Splicing,” Nucleic Acids Research, 1992, vol. 20 (17), pp. 4457-4464. |
| Barany, F., “The Ligase Chain Reaction in a PCR World,” PCR Methods and Applications, 1991, vol. 1 (1), pp. 5-16. |
| Beggs, A.H., et al., “Detection of 98% of DMD/BMD Gene Deletions by Polymerase Chain Reaction,” Human Genetics, 1990, vol. 86 (1), pp. 45-48. |
| Beggs, et al., “Homo sapiens Dystrophin (DMD) Gene, Exon 55 and Partial CDS,” National Center for Biotechnology Information, Database Gen Bank [Online], Gen Bank Accession No. AF213440.1, 2 pages, Jan. 27, 2002. |
| Bijvoet, A.G., et al., “Recombinant Human Acid a-Glucosidase: High Level Production in Mouse Milk, Biochemical Characteristics, Correction of Enzyme Deficiency in GSDII KO Mice.,” Human Molecular Genetics, 1998, vol. 7 (11), pp. 1815-1824. |
| Bionity.com, “Leiden University Medical Center and Prosensa B.V. Announce First Successful Clinical Study with RNA-based Therapeutic PRO051,” Jan. 3, 2008, 1 page, http://www.bionity.com/news/e/76185. |
| Biopharmaceutiques, Merging Pharma & Biotech, Edition 48, 3 pages, Jan. 10, 2008, http://www.biogharmaceutigues.com/en/num/48.html. |
| Biospace, “Leiden University Medical Center and ProSensa B.V. Announce the New England Journal of Medicine Publication of First Successful Clinical Study with RNA-based Therapeutic PRO051 in Duchenne Muscular Dystrophy,” 2 pages, http://www.biosgace.com/news grint.asgx?NewsEntityID=81383, Dec. 27, 2007. |
| Boado, R., et al., “Antisense-Mediated Down-Regulation of the Human Huntingtin Gene,” The Journal of Pharmacology and Experimental Therapeutics, vol. 295, No. 1, pp. 239-243, 2000. |
| Board of Patent Appeals and Interferences, Ex parte Kimishige Ishizaka, Christine L. Martens and Kevin W. Moore, 24 U.S.P.Q.2d 1621, Appeal No. 91/2539, pp. 1-10, Apr. 30, 1992. |
| Board; of Patent Appeals and Interferences., “Ex parte Olav A. Kristense, 10 U.S.P.Q.2d 1701, Appeal No. 87-0697, pp. 1-5, Jan. 17, 1989”, Board of Patent Appeals and Interferences, Jan. 17, 1989, 1-10. |
| Board; of Patent Appeals and Interferences., “Ex parte Prebin M. Remark, 15 U.S.P.Q.2d 1498, Appeal No. 87-2422, pp. 1-12, Jan. 25, 1990”, Board of Patent Appeals and Interferences, 1-12. |
| Bonifazi, E., et al., “Use of RNA Fluorescence In Situ Hybridization in the Prenatal Molecular Diagnosis of Myotonic Dystrophy Type I,” Clinical Chemistry, vol. 52 (2), pp. 319-322, 2006. |
| Braida, C., et al., “Variant CCG and GGC Repeats Within the CTG Expansion Dramatically Modify Mutational Dynamics and Likely Contribute Toward Unusual Symptoms in Some Myotonic Dystrophy Type 1 Patients,” Human Molecular Genetics, vol. 19, No. 8, pp. 1399-1412, Jan. 2010. |
| Bremmer-Bout, M., et al., “Targeted Exon Skipping in Transgenic hDMD Mice: A Model for Direct Preclinical Screening of Human-Specific Antisense Oligonucleotides,” Molecular Therapy, vol. 10, No. 2, pp. 232-240, Aug. 2004. |
| Brett, D., et al., “EST Comparison Indicates 38% of Human mRNAs Contain Possible Alternative Splice Forms,” FEBS Letters, vol. 474 (1), pp. 83-86, 2000. |
| Brolin, C., et al., “Antisense mediated exon skipping therapy for duchenne muscular dystrophy (DMD),” Artificial DNA, RNA & XNA, vol. 2, No. 1, pp. 6-15, Jan. 2011. |
| Brown, M.D., et al., “Gene Delivery with Synthetic (Non Viral) Carriers,” International Journal of Pharmaceutics, vol. 229 (1-2), pp. 1-21, 2001 (Abstract). |
| Buck, G.A., et al., “Design Strategies and Performance of Custom DNA Sequencing Primers,” BioTechniques, vol. 27 (3), pp. 528-536, 1999. |
| Buczko, W., et al., “Modulation of Plasminogen Activator Inhibitor Type-1 Biosynthesis in Vitro and in Vivo with Oligo(nucleoside phosphorothioate)s and Related Constructs,” pharmacology & Therapeutics, vol. 76, No. 1-3, pp. 161-175, 1997. |
| Burnett, R., et al., “DNA Sequence-Specific Polyamides Alleviate Transcription Inhibition Associated with Long GAA-TTC Repeats in Friedreich's Ataxia,” Proceedings of the National Academy of Sciences of the United States of America, 2006, vol. 103 (31), pp. 11497-11502. |
| Canadian Intellectual Property Office, Office Action for Canadian Patent Application No. 2,524,255, 2 pages, dated Jul. 6, 2011. |
| Caplen, N.J., et al., “Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-mediated RNA Interference Human Molecular Genetics,” Human Molecular Genetics, 2002, vol. 11 (2), pp. 175-184. |
| Cartegni, L., et al., “Correction of Disease-Associated Exon Skipping by Synthetic Exon-Specific Activators,” Nature Structural Biology, vol. 10 (2), pp. 120-125, 2003. |
| Cartegni, L., et al., “Listening to Silence and Understanding Nonsense: Exonic Mutations that Affect Splicing,” Nature Review Genetics, 2002, vol. 3 (4), pp. 285-298. |
| Case-Green, S.C., et al., “Studies on the Base Pairing Properties of Deoxyinosine by Solid Phase Hybridisation to Oligonucleotides,” Nucleic Acids Research, vol. 22 (2), pp. 131-136, 1994. |
| Cavanaugh, D.L., Third-Party Submission Under 35 U.S.C. §122(e) and 37 C.F.R. § 1.290 for U.S. Appl. No. 11/233,495, 6 pages, Jun. 5, 2013. |
| Chamberlain, “Dystrophin Levels Required for Genetic Correction of Duchenne Muscular Dystrophy,” Basic and Applied Myology, vol. 7 (3-4), pp. 251-255, 1997. |
| Chaubourt, E., et al., “Muscular Nitric Oxide Synthase (muNOS) and Utrophin,” Journal of Physiology Paris, 2002, vol. 96 (1-2), pp. 43-52. |
| Cooper, T.A., “Neutralizing Toxic RNA,” Science, vol. 325, pp. 272-273, Jul. 2009. |
| Coulter, L.R., et al., “Identification of a New Class of Exonic Splicing Enhancers by In Vivo Selection,” Molecular and Cellular Biology, 1997, vol. 17 (4), pp. 2143-2150. |
| Crooke, S.T., “Basic Principles of Antisense Therapeutics, Handbook of Experimental Pharmacology: Antisense Research and Application,” Springer-Verlag Berlin Heidelberg, 1998, vol. 131, pp. 1-50. |
| Dahlqvist, C., et al., “Functional Notch Signaling is Required for BMP4-Induced Inhibition of Myogenic Differentiation.,” Development, 2003, vol. 130 (24), pp. 6089-6099. |
| Deangelis, F.G., et al., “Chimeric snRNA Molecules Carrying Antisense Sequences Against the Splice Junctions of Exon 51 of the Dystrophin Pre-mRNAInduce Exon Skipping and Restoration of a Dystrophin Synthesis in Δ48-50 DMD Cells,” Proceedings of the National Academy of Sciences of the United States of America, Jul. 9, 2002, vol. 99 (14), pp. 9456-9461. |
| Denny, P., et al., “Oligo-Riboprobes. Tools for in Situ Hybridization,” Histochemistry, 1988, vol. 89 (5), pp. 481-483. |
| Devor, E.J., et al., “Oligonucleotide Yield, Resuspension, and Storage,” Integrated DNA Technologies, pp. 1-11, 2005. |
| Dickson, G., et al., “Screening for Antisense Modulation of Dystrophin Pre-mRNA Splicing,” Neuromuscular Disorders, 2002, vol. 12 (Suppl 1), pp. S67-S70. |
| Dinham, R., Opinion Under Section 74(A) in relation to Patent No. EP (UK) 1619249 in the name of Academisch Ziekenhuis Leiden, 14 pages, Jun. 4, 2009. |
| Dirksen, W.P., et al., “Mapping the SF2/ASF Binding Sites in the Bovine Growth Hormone Exonic Splicing Enhancer,” The Journal of Biological Chemistry, 2000, vol. 275 (37), pp. 29170-29177. |
| Dorchies, O.M., et al., Green Tea Extract and its Major Polyphenol (-)-Epigallocatechin Gallate Improve Muscle Function in a Mouse Model for Duchenne Muscular Dystrophy, American Journal of Physiology—Cell Physiology, vol. 290 (2), pp. C616-C625, 2006. |
| Duboc, D., et al., “Effect of Perindopril on the Onset and Progression of Left Ventricular Dysfunction in Duchenne Muscular Dystrophy,” Journal of the American College of Cardiology, 2005, vol. 45 (6), pp. 855-857. |
| Dubowitz, V., “Foreword,” Neuromuscular Disorders, 12, pp. S1-S2, 2002. |
| Dubowitz, V., “Special Centennial Workshop—101st ENMC International Workshop: Therapeutic Possibilities in Duchenne Muscular Dystrophy, Nov. 30-Dec. 2, 2001, Naarden, The Netherlands,” Neuromuscular Disorders, vol. 12, pp. 421-431, 2002. |
| Dunckley, M.G., et al., “Modification of Splicing in the Dystrophin Gene in Cultured Mdx Muscle Cells by Antisense Oligoribonucleotides,” Human Molecular Genetics, 1995, vol. 5 (1 ), pp. 1083-1090. |
| Dunckley, M.G., et al., “Modulation of Splicing in the DMD Gene by Antisense Oligoribonucleotides,” Nucleosides & Nucleotides, 1997, vol. 16 (7-9), pp. 1665-1668. |
| Ede, N.J., et al., “Routine Preparation of Thiol Oligonucleotides: Application to the Synthesis of Oligonucleotide-Peptide Hybrids,” Bioconjugate Chemistry, 1994, vol. 5 (4), pp. 373-378. |
| Eder, I.E., et al., “Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides,” Cancer Gene Therapy, vol. 7, No. 7, pp. 997-1007, 2000. |
| El-Andaloussi, S., et al., “Induction of Splice Correction by Cell-Penetrating Peptide Nucleic Acids,” The Journal of Gene Medicine, 2006, vol. 8 (10), pp. 1262-1273 (Abstract). |
| Erba, H.P., et al., “Structure, Chromosome Location, and Expression of the Human y-Actin Gene: Differential Evolution, Location, and Expression of the Cytoskeletal 13- and y-Actin Genes,” Molecular and Cellular Biology, 1988, vol. 8 (4), pp. 1775-1789. |
| Errington, S.J., et al., “Target Selection for Antisense Oligonucleotide Induced Exon Skipping in the Dystrophin Gene,” The Journal of Gene Medicine, 2003, vol. 5 (6), pp. 518-527. |
| Espinos, E., et al., “Efficient Non-Viral DNA-Mediated Gene Transfer to Human Primary Myoblasts Using Electroporation,” Neuromuscular Disorders, 2001, vol. 11 (4), pp. 341-349. |
| European Patent Office, Communication pursuant to Article 94(3) EPC, Application No. 10177969.2-1404, dated Aug. 22, 2013, 5 pages. |
| European Patent Office, Communication pursuant to Article 94(3) EPC, Application No. 10718717.1-1401, dated Dec. 19, 2013, 5 pages. |
| European Patent Office, Decision to refuse a European Patent application, Application No. 01979073.2-1402, dated Jan. 7, 2015, 10 pages. |
| European Patent Office, European Search Report, Annex, Application No. EP 03077205, dated Dec. 10, 2003, 6 pages. |
| European Patent Office, Extended European Search Report, Application No. 10177969.2-2401, dated Dec. 16, 2010, 7 pages. |
| European Patent Office, International Search Report, International Application No. PCT/NL2008/050673, dated Feb. 9, 2009, 8 pages. |
| European Patent Office, International Search Report, PCT/NL2013/050306, dated Jul. 19, 2013, 6 pages. |
| European Patent Office, Office Action for European Patent Application No. EP05076770.6, 5 pages, dated Jan. 29, 2007. |
| European Patent Office, Translation of Japanese Patent Application No. 2000-125448 (D64), 31 pages, dated Sep. 27, 2000. |
| European Patent Office, Translation of Japanese Patent Application No. 2000-256547 (D66), 42 pages, dated Aug. 23, 2001. |
| Evers, M.M., et al.,“Targeting Several CAG Expansion Diseases by a Single Antisense Oligonucleotide,” PLoS ONE, vol. 6 (9), pp. 1-11, Sep. 2011. |
| Fainsod, A., et al., “The Dorsalizing and Neural Inducing Gene Follistatin is an Antagonist of BMP-4,” Mechanisms of Development, 1997, vol. 63 (1), pp. 39-50. |
| Federal Angecy for Medicines and Heal th Products, Letter from Federal Agency for Medicines and Health Products to Prosensa, regarding a Phase 1/11, open label, escalating dose, pilot study to assess the effect, safety, tolerability and pharmacokinetics of multiple subcutaneous doses of PRO051 in patients with Duchenne muscular dystrophy, 2 pages, Jan. 9, 2008. |
| Feener, C.A., et al., “Alternative Splicing of Human Dystrophin mRNA Generates lsoforms at the Carboxy Terminus,” Nature, 1989, vol. 338 (6215), pp. 509-511. |
| Fiszer, A., et al., “An Evaluation on Oligonucleotide-Based Therapeutic Strategies for PolyQ Diseases,” BMC Molecular Biology, 2012, vol. 13 (1), pp. 1-12. |
| Fluiter, K., et al., “In Vivo Tumor Growth Inhibition and Biodistribution Studies of Locked Nucleic Acid (LNA) Antisense Oligonucleotides,” Nucleic Acids Research, 2003, vol. 31 (3), pp. 953-962. |
| Fount, M., et al., “Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells,” European Journal of Cancer, vol. 41, No. 4, pp. 624-634, 2005. |
| Fu, Y.H., et al., “An Unstable Triplet Repeat in a Gene Related to Myotonic Muscular Dystrophy,” Science, 1992, vol. 255 (5049), pp. 1256-1258. |
| Furling, D., et al., “Viral Vector Producing Antisense RNA Restores Myotonic Dystrophy Myoblast Functions,” Gene Therapy, 2003, vol. 10 (9), pp. 795-802. |
| Gagnon, K.T., et al, “Allele-Selective Inhibition of Mutant Huntingtin Expression with Antisense Oligonucleotides Targeting the Expanded CAG Repeat,” Biochemistry, 2010, vol. 49 (47), pp. 10166-10178. |
| Galderisi, U., et al., “Antisense Oligonucleotides as Therapeutic Agents,” Journal of Cellular Physiology, 1999, vol. 181 (2), pp. 251-257. |
| Galderisi, U., et al., “Myotonic Dystrophy: Antisense Oligonucleotide Inhibition of DMPK Gene Exression in Vitro,” Biochemical and Biophysical Research Communications, 1996, vol. 221 (3), pp. 750-754. |
| Garcia-Blanco, M.A., et al., “Alternative Splicing in Disease and Therapy,” Nature Biotechnology, May 2004, vol. 22 (5), pp. 535-546. |
| Gen Bank, Accession No. AZ993191.1, 2M0278E12F Mouse 10kb plasmid UUGC2M library Mus muscu genomic clone UUGC2M0278E12 F, genomic survey sequence, entry created and last updated on Apr. 27, 2001, 2 pages. |
| Gen Bank, Accession No. EW162121.1, rfat0126_k17 .y1 fat Sus scrofa cDNA 5-, mRNA sequence, entry created on Aug. 13, 2007, last updated on Mar. 3, 2011, 2 pages. |
| Ghosh, P., et al., “Mannose 6-Phosphate Receptors: New Twists in the Tale,” Natural Reviews Molecular Cell Biology, Mar. 2003, vol. 4 (3), pp. 202-212. |
| Ginjaar, I.B., et al., “Dystrophin Nonsense Mutation Induces Different Levels of Exon 29 Skipping and Leads to Variable Phenotypes within One BMD Family,” European Journal of Human Genetics, 2000, vol. 8 (10), pp. 793-796. |
| Glaxosmithkline, Inc., Press Release, “GSK and Prosensa Announce Primary Endpoint Not Met in Phase Ill Study of Drisapersen in Patients With Duchenne Muscular Dystrophy,” 3 pages, Sep. 20, 2013. |
| Goemans, N.M., et al., “Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy,” The New England Journal of Medicine, vol. 364 (16), pp. 1513-1522, 2011. |
| Gollins, H., et al., “High-Efficiency Plasmid Gene Transfer Into Dystrophic Muscle,” Gene Therapy, 2003, vol. 10 (6), pp. 504-512. |
| Gonzalez-Barriga et al., “Design and Analysis of Effects of Triplet Repeat Oligonucleotides in Cell Models for Myotonic Dystrophy,” vol. 2, No. e81, pp. 1-23, 2013. |
| Grady, D., “Early Drug Test Shows Promise in Treating Muscular Dystrophy,” International Herald Tribune, Jan. 2008, Health and Science, p. 9. |
| Grady, D., Promising Dystrophy Drug Clears Early Test, The New York Times, 2 pages, Dec. 27, 2007. |
| Gramolini, A.O., et al., “Expression of the Utrophin Gene During Myogenic Differentiation,” Nucleic Acids Research, 1999, vol. 27 (17), pp. 3603-3609. |
| Granchelli, J.A., et al., “Pre-Clinical Screening of Drugs Using the mdx Mouse,” Neuromuscular Disorders, 2000, vol. 10 (4-5), pp. 235-239. |
| Gryaznov, S.M., “Oligonucleotide N3′-PS′ Phosphoramidates as Potential Therapeutic Agents,” Biochimica et Biophysica Acta, 1999, vol. 1489, pp. 131-140. |
| Habara, Y., et al., “In Vitro Splicing Analysis Showed that Availability of a Cryptic Splice Site is not a Determinant for Alternative Splicing Patterns Caused by +1 G-A Mutations in Intrans of the Dystrophin Gene,” Journal of Medical Genetics, vol. 46 (8), pp. 542-547, 2009. |
| Hagiwara, Y., et al., “A Novel Point Mutation (G<sup>-1</sup>to T) in a 5′ Splice Donor Site of lntron 13 of the Dystrophin Gene Results in Exon Skipping and is Responsible for Becker Muscular Dystrophy.,” American Journal of Human Genetics, 1994, vol. 54 (1), pp. 53-61. |
| Hanoa, V., et al., “The AUUCU Repeats Responsible for Spinocerebellar Ataxia Type 10 Form Unusual RNA Hairpins,” The Journal of Biological Chemistry, 2005, vol. 280 (32), pp. 29340-29345. |
| Hansen, S., “Product Development—Addition by subtraction,” BioCentury, The Bernstein Report on BioBusiness, Jan. 7, 2008, p. A28. |
| Harding, P.L., et al., “The Influence of Antisense Oligonucleotide Length on Dystrophin Exon Skipping,” Molecular Therapy, Jan. 2007, vol. 15 (1), pp. 157-166. |
| Harrison, J.G., et al., “Synthesis and Hybridization Analysis of a Small Library of Peptide-Oligonucleotide Conjugates,” Nucleic Acids Research, 1998, vol. 26 (13), pp. 3136-3145. |
| Hashol T, L., et al., “Antisense Downregulation of Mutant Huntingtin in a Cell Model,” Journal of Gene Medicine, 2003, vol. 5 (6), pp. 528-538. |
| Hassan, A.B., “Keys to the Hidden Treasures of the Mannose 6-Phosphate/lnsulin-Like ⋅ Growth Factor 2 Receptor,” American Journal of Pathology, Jan. 2003, vol. 162 (1), pp. 3-6. |
| Heemskerk, H., et al., “Development of Antisense-Mediated Exon Skipping as a Treatment for Duchenne Muscular Dystrophy,” Annals of the New York Academy of Sciences, 2009, vol. 1175, pp. 71-79. |
| Heemskerk, H.A., et al., “In Vivo Comparison of 2′-O-Methyl Phosphorothioate and Morpholino Antisense Oligonucleotides for Duchenne Muscular Dystrophy Exon Skipping,” The Journal of Gene Medicine, 2009, vol. 11 (3), pp. 257-266. |
| Heemskerk, H.A., et al., “Preclinical PK and PD Studies on 2′-O-Methyl--phosphorothioate RNA Antisense Oligonucleotides in the mdx Mouse Model,” Molecular Therapy, Jun. 2010, vol. 18 (6), pp. 1210-1217. |
| Henderson, A.M., et al., “The Basic Helix-Loop-Helix Transcription Factor HESR1 Regulates Endothelial Cell Tube Formation,” The Journal of Biological Chemistry, vol. 276 (9), pp. 6169-6176, 2001. |
| Highfield, R., “Roger Highfield rounds up latest snippets of science, from a new treatment for muscular dystrophy, detecting tumours to the benefits of cooking vetables,” Science: Boffin log, Jan. 1, 2008, 5 pages. |
| Hoffman, E.P., “Skipping Toward Personalized Molecular Medicine,” The New England Journal of Medicine, Dec. 2007, vol. 357 (26), pp. 2719-2722. |
| Hoffman, E.P., et al., “Somatic Reversion/Suppression of the Mouse mdx Phenotype in Vivo,” Journal of the Neurological Sciences, 1990, vol. 99 (1), pp. 9-25. |
| Hua, Y., et al., “Antisense Correction of SMN2 Splicing in the CNS Rescues Necrosis in a Type III SMA Mouse Model,” Genes and Development, 2010, vol. 24 (15), pp. 1634-1644. |
| Hussey, N.D., et al., “Analysis of Five Duchenne Muscular Dystrophy Exons and Gender Determination Using Conventional Duplex Polymerase Chain Reaction on Single Cells,” ⋅ Molecular Human Reproduction, 1999, vol. 5 (11), pp. 1089-1094. |
| Hyndman, A.G., “High Affinity Binding of Transferrin in Cultures of Embryonic Neurons from the Chick Retina,” Brain Research, 1991, vol. 564 (1), pp. 127-131. |
| Iezzi, S., et al, “Deacetylase Inhibitors Increase Muscle Cell Size by Promoting Myoblast Recruitment and Fusion through Induction of Follistatin,” Developmental Cell, May 2004, vol. 6 (5), pp. 673-684. |
| Ikezawa, M., et al., “Dystrophin Gene Analysis on 130 Patients with Duchenne Muscular Dystrophy with a Special Reference to Muscle mRNA Analysis,” Brain & Development, 1998, vol. 20 (3), pp. 165-168. |
| International Preliminary Examining Authority—European Patent Office, International Preliminary Examination Report for International Application No. PCT/NL01/00697, 2 pages, dated Aug. 1, 2002. |
| International Searching Authority—European Patent Office, Annex to the European Search Report—Application No. EP03077205, dated Nov. 19, 2003, 1 page. |
| International Searching Authority—US, International Search Report, International Application No. PCT/US10/48532,5 pages, dated Jan. 26, 2011. |
| International Searching Authority—European Patent Office, International Search Report, International Application No. PCT/NL2013/050487, 8 pages, dated Dec. 20, 2013. |
| International Searching Authority—European Patent Office, International Preliminary Report on Patentability and Written Opinion, International Application No. PCT/EP2007/054842, dated Nov. 21, 2008, 8 pages. |
| International Searching Authority—European Patent Office, International Search Report, International Application No. PCT/EP2007/054842 3 pages, dated Aug. 21, 2007. |
| International Searching Authority—European Patent Office, International Search Report, International Application No. PCT/NL 2008/050673, 8 pages, dated Sep. 2, 2009. |
| International Searching Authority—European Patent Office, International Search Report, International Application No. PCT/NL01/00697, 2 pages, dated Dec. 21, 2001. |
| International Searching Authority—European Patent Office, International Search Report, International Application No. PCT/NL2004/000196, 7 pages, dated Oct. 28, 2004. |
| International Searching Authority—European Patent Office, International Search Report, International Application No. PCT/NL2006/000209, 4 pages, dated Oct. 5, 2006. |
| International Searching Authority—European Patent Office, International Search Report, International Application No. PCT/NL2008/050470, 4 pages, dated Jul. 2, 2009. |
| International Searching Authority—European Patent Office, International Search Report, International Application No. PCT/NL2008/050475, 30 pages, Jun. 25, 2009. |
| International Searching Authority—European Patent Office, International Search Report, International Application No. PCT/NL2009/050006, 5 pages, dated Jul. 31, 2009. |
| International Searching Authority—European Patent Office, International Search Report, International Application No. PCT/NL2009/050113, 8 pages, dated Jun. 30, 2010. |
| International Searching Authority—European Patent Office, International Search Report, International Application No. PCT/NL2010/050230, 5 pages, dated Jun. 24, 2010. |
| Ito, T., et al., “One of three Examined Purine-Rich Sequences Selected from Dystrophin Exons Exhibits Splicing Enhancer Activity,” Acta Myologica, 2001, vol. 20, pp. 151-153. |
| Ito, T., et al., “Purine-Rich Exon Sequences are Not Necessarily Splicing Enhancer Sequence in the Dystrophin Gene,” The Kobe Journal of Medical Sciences, Oct. 2001, vol. 47 (5), pp. 193-202. |
| Itoh et al., “Allergic Contact Dermatitis Due to Topical Drugs Contaiing Corticosteroids,” Skin Research, 24(2), pp. 270-271, 1982. |
| Jou, C., et al., “Deletion Detection in the Dystrophin Gene by Multiplex Gap Ligase Chain Reaction and Immunochromatographic Strip Technology,” Human Mutation, 1995, vol. 5 (1), pp. 86-93. |
| Ka Tholieke Universiteit Leuven, Letter from Katholieke Universiteit Leuven to Dr. N. Goemans, Child Neurology regarding Study Phase 1/11, PRO051-02, 5 pages, dated Jan. 22, 2008 (translation provided). |
| Karras, J.G., et al., “Deletion of Individual Exons and Induction of Soluble Murine Interleukin-5 Receptor-a Chain Expression through Antisense Oligonucleotide-Mediated Redirection of Pre-mRNA Splicing,” Molecular Pharmacology, 2000, vol. 58 (2), pp. 380-387. |
| Kendall, G.C., et al., “Dantrolene Enhances Antisense-Mediated Exon Skipping in Human and Mouse Models of Duchenne Muscular Dystrophy,” Science Translational Medicine, vol. 4 (164), 26 pages, Dec. 12, 2012. |
| Kerr, K., et al., “BMP Regulates Skeletal Myogenesis at Two Steps,” Molecular and Cellular Proteomics, 2003, vol. 2 (9), pp. 976. |
| Kinali, M., et al., “Local Restoration of Dystrophin Expression With the Morpholino Oligomer AV1-4658 in Duchenne Muscular Dystrophy: A Single-Blind, Placebo-Controlled, Dose-Escalation, Proof-of-Concept Study,” The Lancet. Neurology, 2009, vol. 8 (10), pp. 918-928. |
| Kohler, W., “Experimenteel middel voor Duchenne,” http://www.nrc.nl/nieuws/2007 /12/27 /exgerimenteel-middel-voor-duchenne-11458530-a1030722, 4 pages w/ English Translation, Dec. 27, 2007. |
| Krain Er, A., Declaration of Dr. Adrian Krainer, 7 pages, Jul. 21, 2010, (submitted in Third Party's Statement for JP Application No. 2002-529499 on Oct. 29, 2010). |
| Kurreck, J., et al., “Design of Antisense Oligonucleotides Stabilized by Locked Nucleic Acids,” Nucleic Acids Research, 2002, vol. 30 (9), pp. 1911-1918. |
| Langlois, M.A., et al., “Hammerhead Ribozyme-Mediated Destruction of Nuclear Foci in Myotonic Dystrophy Myoblasts,” Molecular Therapy, 2003, vol. 7 (5), pp. 670-680. |
| Laptev, A.V., et al., “Specific Inhibition of Expression of a Human Collagen Gene (COL 1A1) with Modified Antisense Oligonucleotides. The Most Effective Target Sites are Clustered in Double Stranded Regions of the Predicted Secondary Structure for the mRNA,” Biochemistry, 1994, vol. 33 (36), pp. 11033-11039. |
| Lebedev, Y., et al.,“Oligonucleotides containing 2-aminoadenine and 5-methylcytosine are more effective as primers for PCR amplification than their nonmodified counterparts,” Genetic Analysis: Biomolecular Engineering, vol. 13, pp. 15-21, 1996. |
| Lee, J.E., et al., “RNase H-Mediated Degradation of Toxic RNA in Myotonic Dystrophy Type 1,” Proceedings of the National Academy of Sciences of the United States of America, Mar. 2012, vol. 109 (11), pp. 4221-4226. |
| Lee, J.H., et al., “Receptor Mediated Uptake of Peptides that Bind the Human Transferrin Receptor,” European Journal of Biochemistry/ FEBS, 2001, vol. 268 (7), pp. 2004-2012. |
| Lewin, B., “Genes VII,” Oxford University Press, 2000, Chapters: 1, 5, 22; pp. 29, 126, 129, 686, 704, 705. |
| Lewin, B., “Nuclear Splicing,” Genes VII, Chapter 22, pp. 704-705, Jan. 2000. |
| Liu, H.X., et al., “A Mechanism for Exon Skipping Caused by Nonsense or Missense Mutations in BRCA1 and Other Genes,” Nature Genetics, Jan. 2001, vol. 27 (1), pp. 55-58. |
| Liu, H.X., et al., “Identification of Functional Exonic Splicing Enhancer Motifs Recognized by Individual SR Proteins,” Genes & Development, 1998, vol. 12 (13), pp. 1998-2012. |
| Liu, W., et al., “Specific Inhibition of Huntington's Disease Gene Expression by siRNAs in Cultured Cells,” Proceedings of the Japan Academy, 2003, vol. 79, pp. 293-298. |
| Liu, Y.C., et al., “Efficiency of DNA Transfection of Rat Heart Myoblast Cells H9c2(2-1) by Either Polyethyleneimine or Electroporation,” Applied Biochemistry and Biotechnology, 2011, vol. 164 (7), pp. 1172-1182. |
| Lonza Cologne AG, “Amaxa Cell Line Nucleofector Kit V” for C2C12, 4 pages, 2009. |
| Lu, Q.L., et al., “Functional Amounts of Dystrophin Produced by Skipping the Mutated Exon in the mdx Dystrophic Mouse,” Nature Medicine, Aug. 2003, vol. 9 (8), pp. 1009-1014. |
| Lu, Q.L., et al., “Massive Idiosyncratic Exon Skipping Corrects the Nonsense Mutation in Dystrophic Mouse Muscle and Produces Functional Revertant Fibers by Clonal Expansion,” The Journal of Cell Biology, 2000, vol. 148 (5), pp. 985-995. |
| Lu, Q.L., et al., “Non-Viral Gene Delivery in Skeletal Muscle: A Protein Factory,” Gene Therapy, 2003, vol. 10 (2), pp. 131-142. |
| Lu, Q.L., et al., “Systemic Delivery of Antisense Oligoribonucleotide Restores Dystrophin Expression in Body-Wide Skeletal Muscles,” Proceedings of the National Academy of Sciences of the United States of America, Jan. 2005, vol. 102 (1), pp. 198-203. |
| Ludolph, D.C., et al., “Transcription Factor Families: Muscling in on the Myogenic Program,” FASEB Journal, 1995, vol. 9 (15), pp. 1595-1604. |
| Magana, J.J., et al., “Perspectives on Gene Therapy in Myotonic Dystrophy Type 1,” Journal of Neuroscience Research, 2011, vol. 89 (3), pp. 275-285. |
| Mann, C.J., et al., “Antisense-lnduced Exon Skipping and Synthesis of Dystrophin in the mdx Mouse,” Proceedings of the National Academy of Sciences of the United States of America, Jan. 2001, vol. 98 (1), pp. 42-47. |
| Mann, C.J., et al., “Improved Antisense Oligonucleotide Induced Exon Skipping in the mdx Mouse Model of Muscular Dystrophy,” The Journal of Gene Medicine, 2002, vol. 4 (6), pp. 644-654. |
| Martin, F.H., et al., “Base Pairing Involving Deoxyinosine: Implications for Probe Design,” Nucleic Acids Research, vol. 13 (24), pp. 8927-8938, 1985. |
| Martini UK, F., et al., “Correction of Glycogen Storage Disease Type II by Enzyme Replacement with a Recombinant Human Acid Maltase Produced by Over-Expression in a CHO-DHFR(Neg) Cell Line,” Biochemical and Biophysical Research Communications, Oct. 2000, vol. 276 (3), pp. 917-923 (Abstract). |
| Matsuo, M., “Duchenne/Becker Muscular Dystrophy: From Molecular Diagnosis to Gene Therapy,” Brain & Development, 1996, vol. 18 (3), pp. 167-172. |
| Matsuo, M., et al., “Duchenne and Becker Muscular Dystrophy: From Gene Diagnosis to Molecular Therapy,” IUBMB Life, 2002, vol. 53 (3), pp. 147-152. |
| Matsuo, M., et al., “Exon Skipping during Splicing of Dystrophin mRNA Precursor due to an lntraexon Deletion in the Dystrophin Gene of Duchenne Muscular Dystrophy Kobe,” The Journal of Clinical Investigation, 1991, vol. 87 (6), pp. 2127-2131. |
| Matsuo, M., et al., “Partial Deletion of a Dystrophin Gene Leads to Exon Skipping and to Loss of an Intra-Exon Hairpin Structure from the Predicted mRNA Precursor,” Biochemical and Biophysical Research Communications, 1992, vol. 182 (2), pp. 495-500. |
| Matteucci, M., “Structural Modifications Toward Improved Antisense Oligonucleotides,” Perspective in Drug Discovery and Design, 1996, vol. 4 (1), pp. 1-16. |
| McClorey, G., et al., “Antisense Oligonucleotide-lnduced Exon Skipping Restores Dystrophin Expression in Vitro in a Canine Model of DMD,” Gene Therapy, vol. 13, pp. 1373-1381, 2006. |
| McClorey, G., et al., “Induced Dystrophin Exon Skipping in Human Muscle Explants,” Neuromuscular Disorders, 2006, vol. 16 (9-10), pp. 583-590. |
| Medical News Today, “New Clinical Trial Results Show How Personalized Medicine Will Alter Treatment of Genetic Disorders,” http://www.medicalnewstoday.com/releases/92777.php 2 pages, Dec. 29, 2007. |
| Miller, K.J., et al., “Antisense Oligonucleotides: Strategies for Delivery,” Pharmaceutical Science and Technology Today, Dec. 1998, vol. 1 (9), pp. 377-386. |
| Monaco, A.P., et al., “An Explanation for the Phenotypic Differences between Patients Bearing Partial Deletions of the DMD Locus,” Genomics, 1988, vol. 2 (1 ), pp. 90-95. |
| Moon, I.J., et al., “Target Site Search and Effective Inhibition of Leukaemic Cell Growth by a Covalently Closed Multiple Anti-Sense Oligonucleotide to c-myb,” The Biochemical Journal, 2000, vol. 346, pp. 295-303. |
| Mulders, S.A., et al., “Molecular Therapy in Myotonic Dystrophy: Focus on RNA Gain-of Function,” Human Molecular Genetics, 2010, vol. 19 (R1), pp. R90-R97. |
| Mulders, S.A., et al., “Triplet-Repeat Oligonucleotide-Mediated Reversal of RNA Toxicity in Myotonic Dystrophy,” Proceedings of the National Academy of Sciences of the United States of America, Aug. 2009, vol. 106 (33), pp. 13915-13920. |
| Munroe, S.H., “Antisense RNA Inhibits Splicing of Pre-mRNA in Vitro,” The EMBO Journal, 1988, vol. 7 (8), pp. 2523-2532. |
| Muntoni, F., et al., “149th ENMC International Workshop and 1st TREAT-NMD Workshop on: “Planning Phase 1/11 Clinical trials using Systemically Delivered Antisense Oligonucleotides in Duchenne Muscular Dystrophy”,” Neuromuscular Disorders, 2008, vol. 18, pp. 268-275. |
| Muntoni, F., et al., “A Mutation in the Dystrophin Gene Selectively Affecting Dystrophin Expression in the Heart,” The Journal of Clinical Investigation, Aug. 1995, vol. 96 (2), pp. 693-699. |
| Muntoni, F., et al., “Targeting RNA to Treat Neuromuscular Disease,” Nature Reviews Drug Discovery, Aug. 2011, vol. 10 (8), pp. 621-637. |
| Nakamori, M, et al., “Stabilization of Expanded (CTG)⋅(CAG) Repeats by Antisense Oligonucleotides,” Molecular Therapy, vol. 19, No. 12, pp. 2222-2227, Dec. 2011. |
| Nakamura, A., et al., “Exon Skipping Therapy for Duchenne Muscular Dystrophy,” Neuropathology, 2009, vol. 29 (4), pp. 494-501. |
| Nakamura, et al., “The Latest Finding on Muscular Dystrophy,” Medical Online, vol. 42, No. 4, pp. 382-386, 2008 (English translation attached 5 pgs.). |
| Nederlandsch Octrooibureau, “Comparative analysis of AONs for inducing the skipping of exon 45 or 53 from the dystrophin gene in human control muscle cells,” EP1619249, 3 pages, Aug. 23, 2013. |
| Nederlandsch Octrooibureau, “Comparative Analysis of AONs for inducing the skipping of exon 53 from the dystrophin gene in human control muscle cells,” EP1619249, 3 ⋅ pages, Jan. 8, 2014. |
| Nederlandsch Octrooibureau, Exon 45 Alignment—EP1619249, 1 page, Aug. 23, 2013. |
| Nederlandsch Octrooibureau, Exon 46 Alignment—EP1619249, 1 page, Aug. 23, 2013. |
| Nederlandsch Octrooibureau, Grounds of Appeal—EP1619249, 16 pages, Aug. 23, 2013. |
| Nederlandsch Octrooibureau, List of all submitted documents—EP1619249, 4 pages, Jan. 8, 2014. |
| Nederlandsch Octrooibureau, List of all submitted documents—EP1619249, 4 pages, Aug. 23, 2013. |
| Nederlandsch Octrooibureau, Patentee Letter in EP1619249 Opposition Appeal Proceedings, 25 pages, Jun. 10, 2014. |
| Nederlandsch Octrooibureau, Patentee's Letter in Response to EPO Communication regarding EP 13170245.8, 4 pages, Apr. 15, 2015. |
| Nederlandsch Octrooibureau, Patentee's Letter in Response to EPO Communication regarding EP 13170245.8, 5 pages, Oct. 20, 2014. |
| Nederlandsch Octrooibureau, Patentee's response to communication dated Jul. 29, 2009 from the Opposition Division of EPO in relation to European Patent Application (EP 05076770.6), Jan. 27, 2010, 41 pages. |
| Nederlandsch Octrooibureau, Reply to the Grounds of Appeal—EP1619249, 35 pages, Jan. 8, 2014. |
| Nederlandsch Octrooibureau, Response to Communication pursuant to Article 94(3) EPC, European Patent Application No. 10718717 .1, Apr. 14, 2014, 3 pages. |
| Nederlandsch Octrooibureau, Response to Communication pursuant to Rule 161 (2) and Rule 162 EPC, European Patent Application No. 10718717.1, Jun. 4, 2012, 3 pages. |
| Nederlandsch Octrooibureau, Sequence of Exon 53, putative SES fragments and oligonucleotides—EP1619249, D75, 1 page, Aug. 23, 2013. |
| Nederlandsch Octrooibureau, Sequence of Exon 53, putative SES fragments and oligonucleotides further comprising oligonucleotides of WO 2006/000057, EP1619249, D86, 1 page, Jan. 8, 2014. |
| Nelson et al., “The Properties of Nucleotide Bases Affect the Three-Dimensional Structure of Nucleic Acids,” Lehninger Principles of Biochemistry, Third Edition, p. 331, 2000. |
| Neue Zurcher Zeitung AG, “New Treatment Approach to Rare Muscle Disease,” 4 pages, Jan. 9, 2008 (with English Translation). |
| Nishio, H., et al., “Identification of a Novel First Exon in the Human Dystrophin Gene and of a New Promoter Located More Than 500 Kb Upstream of the Nearest Known Promoter,” The Journal of Clinical Investigation, 1994, vol. 94 (3), pp. 1037-1042. |
| Office Action for U.S. Appl. No. 11/233,495 dated Mar. 19, 2008. |
| Office Action for U.S. Appl. No. 11/233,495 dated May 29, 2009. |
| Opalinska, J.B., et al., “Nucleic-Acid Therapeutics: Basic Principles and Recent Applications,” Nature Reviews. Drug Discovery, Jul. 2002, vol. 1 (7), pp. 503-514. |
| O'Shaughnessy, J., et al., “Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase Ill Trial Results,” Journal of Clinical Oncology, 2002, vol. 20 (12), pp. 2812-2823. |
| Oxford Dictionary of English, 2nd Edition, Revised, Oxford University Press, p. 158, 2005. |
| Pasternak et al., “A chemical synthesis of LNA-2, 6-diaminopurine riboside, and the influence of 2′-O-methyl-2, 6-diaminopurine and LNA-2, 6-diaminopurine ribosides on the thermodynamic properties of 2′-O-methyl RNA/RNA heteroduplexes,” Nucleic Acids Research, vol. 35, No. 12, pp. 4055-4063, 2007. |
| Patel, K., et al., “The Function of Myostatin and Strategies of Myostatin Blockade—New Hope for Therapies Aimed at Promoting Growth of Skeletal Muscle,” Neuromuscular Disorders, 2005, vol. 15 (2), pp. 117-126. |
| Patent Trial and Appeal Board, Declaration—37 C.F.R., §41.203(b), 7 pages, entered Jul. 18, 2014. |
| Patent Trial and Appeal Board, Standing Order, Entered Mar. 8, 2011, 81 pages. |
| Patent Trial and Appeal Board, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), Decision—Motions—37 C.F.R. § 41.125(a), 53 pages, entered Apr. 29, 2016 [Patent Interference No. 106,007 (RES)]. |
| Patent Trial and Appeal Board, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), Decision—Motions—37 C.F.R. § 41.125(a) (Substitute), 53 pages, entered May 12, 2016 [Patent Interference No. 106,007 (RES)]. |
| Patent Trial and Appeal Board, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), Errata, filed May 23, 2016, 2 pages [Patent Interference No. 106,007 (RES)]. |
| Patent Trial and Appeal Board, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), Judgment—Motions—37 C.F.R. § 41.127, 3 pages, entered Apr. 29, 2016 [Patent Interference No. 106,007 (RES)]. |
| Patent Trial and Appeal Board, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), Redeclaration—37 C.F.R. § 41.203(c), 2 pages, entered Apr. 29, 2016 [Patent Interference No. 106,007 (RES)]. |
| Patent Trial and Appeal Board, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495); University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), Order—Oral Argument—37 C.F.R. § 41.124, 2 pages, entered Mar. 29, 2016 [Patent Interference Nos. 106,007 (RES) and 106,008 (RES)]. |
| Patent Trial and Appeal Board, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), Withdrawal and Reissue of Decision on Motions, 2 pages, entered May 12, 2016 [Patent Interference No. 106,007 (RES)]. |
| Patent Trial and Appeal Board, University of Western Australia (U.S. Pat. No. 8,486,907) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 14/198,992), Decision—Priority—37 CFR § 41.125(a), 18 pages, entered Sep. 29, 2015 [Patent Interference No. 106,013 (RES)]. |
| Patent Trial and Appeal Board, University of Western Australia (U.S. Pat. No. 8,486,907) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 14/198,992), Judgment—37 CFR § 41.127, 2 pages, entered Sep. 29, 2015 [Patent Interference No. 106,013 (RES)]. |
| Patent Trial and Appeal Board, University of Western Australia (U.S. Pat. No. 8,486,907) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 14/198,992), Order to Show Cause—37 C.F.R. § 41.104(a), 3 pages, Jun. 22, 2015 [Patent Interference No. 106,013 (RES)]. |
| Patent Trial and Appeal Board, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), Declaration 37 C.F.R. § 41.203(b), entered Jul. 24, 2014, 7 pages [Patent Interference No. 106,008 (RES)]. |
| Patent Trial and Appeal Board, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), Order—Motion Times—37 CFR §41.104(C), entered Jul. 24, 2014, 6 pages [Patent Interference No. 106,008 (RES)]. |
| Patent Trial and Appeal Board, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. 13/550,210), Decision—Motions 37 C.F.R. § 41.125(a), 20 pages, Sep. 20, 2016 [Patent Interference No. 106,008 (RES)]. |
| Patent Trial and Appeal Board, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), Judgment—Motions 37 C.F.R. § 41.127, entered Sep. 20, 2016, 3 pages [Patent Interference No. 106,008 (RES)]. |
| Patent Trial and Appeal Board,University of Western Australia (U.S. Pat. No. 8,486,907) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 14/198,992), Decision—Motions—37 C.F.R. § 41.125(a), 12 pages, Jun. 22, 2015 [Patent Interference No. 106,013 (RES)]. |
| Peterson, TC., et al., “Selective Down-Regulation of c-jun Gene Expression by Pentoxifylline and c-jun Antisense Interrupts Platelet-Derived Growth Factor Signaling: Pentoxifylline Inhibits Phosphorylation of c-Jun on Serine 73,” Molecular Pharmacology, 2002, vol. 61 (6), pp. 1476-1488. |
| Phillips, M.I., “Antisense Inhibition and Adena-Associated Viral Vector Delivery for Reducing Hypertension,” Hypertension, 1997, vol. 29 (1 Pt 2), pp. 177-187. |
| Politano, L., et al., “Gentamicin Administration in Duchenne Patients With Premature Stop Codon. Preliminary Results,” Acta Myologica, 2003, vol. 22 (1), pp. 15-21. |
| Popplewell Information Disclosure Statement for U.S. Appl. No. 14/045,841, filed Sep. 1, 2015, 3 pages, (attached non-patent literature document, 1 page). |
| Popplewell, L.J., et al., “Design of phosphorodiamidate morpholino oligomers (PMOs) for the Induction of exon skipping of the human DMD gene,” (Abstract), Human Gene Therapy, 19(10), Oct. 2008. |
| Popplewell, L.J., et al., “Design of Phosphorodiamidate Morpholino Oligomers (PMOs) for the Induction of Exon Skipping of the Human DMD Gene,” Molecular Therapy, Mar. 2009, vol. 17 (3), pp. 554-561. |
| Popplewell, L.J., et al., Poster of “Design of Phosphorodiamidate Morpholino Oligomers (PMOs) for the Induction of Exon Skipping of the Human DMD Gene,” 5th Annual Conference of the British Society for Gene & Cell Therapy, Apr. 7-9, 2008, 1 page. |
| Pramono, Z.A., et al., “Induction of Exon Skipping of the Dystrophin Transcript in Lymphoblastoid Cells by Transfecting an Antisense Oligodeoxynucleotide Complementary to an Exon Recognition Sequence,” Biochemical and Biophysical Research Communications, 1996, vol. 226 (2), pp. 445-449. |
| Radley, H.G., et al., “Duchenne Muscular Dystrophy: Focus on Pharmaceutical and Nutritional Interventions,” The International Journal of Biochemistry & Cell Biology, 2007, vol. 39 (3), pp. 469-477. |
| Rando, T.A., “Oligonucleotide-Mediated Gene Therapy for Muscular Dystrophies,” Neuromuscular Disorders, 2002, vol. 12 (Suppl 1), pp. S55-S60. |
| Redorbit News, “LUMC and Prosensa Report Positive Results of DMD Study,” Dec. 28, 2007, 1 page. |
| Reitter, B., “Deflazacort vs. Prednisone in Duchenne Muscular Dystrophy: Trends of an Ongoing Study,” Brain & Development, 1995, vol. 17 Suppl, pp. 39-43. |
| Reuser, A.J., et al., “Uptake and Stability of Human and Bovine Acid a-Glucosidase in Cultured Fibroblasts and Skeletal Muscle Cells from Glycogenosis Type II Patients,” Experimental Cell Research, 1984, vol. 155 (1), pp. 178-189. |
| Rhodes, J., “Biomarin Bulks Up,” Biocentury, pp. 6-8, Dec. 8, 2014. |
| Rigo, F., et al., “Antisense Oligonucleotide-Based Therapies for Diseases Caused by premRNA Processing Defects,” Advances in Experimental Medicine and Biology, 2014, vol. 825, pp. 303-352. |
| Roberts, R.G., et al., “Direct Detection of Dystrophin Gene Rearrangements by Analysis of Dystrophin mRNA in Peripheral Blood Lymphocytes,” American Journal of Human Genetics, 1991, vol. 49 (2), pp. 298-310. |
| Roberts, R.G., et al., “Direct Diagnosis of Carriers of Duchenne and Becker Muscular Dystrophy by Amplification of Lymphocyte RNA,” Lancet, 1990, vol. 336 (8730), pp. 1523-1526. |
| Roberts, R.G., et al., “Exon Structure of the Human Dystrophin Gene,” Genomics, 1993, vol. 16 (2), pp. 536-538. |
| Roberts, R.G., et al., “Searching for the 1 in 2,400,000: A Review of Dystrophin Gene Point Mutations,” Human Mutation, 1994, vol. 4 (1), pp. 1-11. |
| Rolland, J.F., et al., “Overactivity of Exercise-Sensitive Cation Channels and their Impaired Modulation by IGF-1 in mdx Native Muscle Fibers: Beneficial Effect of Pentoxifylline,” Neurobiology of Disease, 2006, vol. 24 (3), pp. 466-474. |
| Rosen, G., et al., “Combination Chemotherapy and Radiation Therapy in the Treatment of Metastatic Osteogenic Sarcoma,” Cancer, 1975, vol. 35 (3), pp. 622-630. |
| Sah, D.W., et al., “Oligonucleotide Therapeutic Approaches for Huntington Disease,” The Journal of Clinical Investigation, Feb. 2011, vol. 121 (2), pp. 500-507. |
| Samoylova, T., et al., “Elucidation of Muscle-Binding Peptides by Phage Display Screening,” Muscle & Nerve, Apr. 1999, vol. 22 (4), pp. 460-466. |
| Sarepta Therapeutics Inc., Notice of Opposition to European patent EP 2636741 B1, 72 pages, Jan. 27, 2017. |
| Sarepta Therapeutics, Inc., “Sarepta Therapeutics and University of Western Australia Announce Exclusive Worldwide Licensing Agreement for Exon-Skipping Program in Duchenne Muscular Dystrophy,” News Release, EP1619249, 3 pages, Apr. 2013. |
| Sarepta Therapeutics, Inc., Third party observations pursuant to Article 115 EPC and Rule 114 EPC against European patent application EP 10718717 .1, Oct. 16, 2015, 19 pages. |
| Scanlon, K.J., “Anti-Genes: siRNA, Ribozymes and Antisense,” Current Pharmaceutical Biotechnology, 2004, vol. 5 (5), pp. 415-420. |
| Schnell, F., “Declaration of Dr. Fred Schnell in Support of Appeal of the Opposition Division's Decision to Maintain EP-1619249 in amended form,” 6 pages, Jan. 8, 2014. |
| Segalat, L., et al., “CAPON Expression in Skeletal Muscle is Regulated by Position, Repair, NOS Activity, and Dystrophy,” Experimental Cell Research, 2005, vol. 302 (2), pp. 170-179. |
| Sertic, J., et al., “Deletion Screening of the Duchenne/Becker Muscular Dystrophy Gene in Croatian Population,” Collegium Antropologicum, 1997, vol. 21 (1), pp. 151-156. |
| Shapiro, M.B., et al., “RNA Splice Junctions of Different Classes of Eukaryotes: Sequence Statistics and Functional Implications in Gene Expression,” Nucleic Acids Research, 1987, vol. 15 (17), pp. 7155-7174. |
| Sherratt, T.G., et al., “Exon Skipping and Translation in Patients with Frameshift Deletions in the Dystrophin Gene,” American Journal of Human Genetics, 1993, vol. 53 (5), pp. 1007-1015. |
| Shiga, N., et al., “Disruption of the Splicing Enhancer Sequence within Exon 27 of the Dystrophin Gene by a Nonsense Mutation Induces Partial Skipping of the Exon and is Responsible for Becker Muscular Dystrophy,” The Journal of Clinical Investigation, Nov. 1997, vol. 100 (9), pp. 2204-2210. |
| Simoes-Wust, A.P., et al., “bcl-xL Antisense Treatment Induces Apoptosis in Breast Carcinoma Cells,” International Journal of Cancer, 2000, vol. 87 (4), pp. 582-590. |
| Singh, V., et al., “Proportion and Pattern of Dystrophin Gene Deletions in North Indian Duchenne and Becker Muscular Dystrophy Patients,” Human Genetics, vol. 99 (2), pp. 206-208, 1997. |
| Sironi, M., et al., “The Dystrophin Gene is Alternatively Spliced Throughout its Coding Sequence,” FEBS Letters, 2002, vol. 517 (1-3), pp. 163-166. |
| Smith, B.F., et al., “Muscle-specific Peptide #5,” XP-002442550, 1 pages, Mar. 23, 1999. |
| Sontheimer, E.J., University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), 3rd Declaration of Erik J. Sontheimer, Ph.D. 123 pages, filed Feb. 17, 2015 [Patent Interference No. 106,007 (RES)]. |
| Sontheimer, Erik, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), Declaration of Erik Sontheimer, Ph.D., 112 pages, Nov. 17, 2014 [Patent Interference No. 106,008 (RES)]. |
| Spitali, P., et al., “Exon Skipping-Mediated Dystrophin Reading Frame Restoration for Small Mutations,” Human Mutation, vol. 30 (11), pp. 1527-1534, 2009. |
| Squires, K.E., “An Introduction to Nucleoside and Nucleotide Analogues,” Antiviral Therapy, 2001, vol. 6 (Suppl. 3), pp. 1-14. |
| Sterrenburg, E., et al., “Gene Expression Profiling Highlights Defective Myogenesis in DMD Patients and a Possible Role for Bone Morphogenetic Protein 4,” Neurobiology of Disease, vol. 23 (1), pp. 228-236, 2006. |
| Summerton, J., “Morpholino Antisense Oligomers: The Case for an RNase H-Independent Structural Type,” 1999, vol. 1489 (1), pp. 141-158. |
| Summerton, J., et al., “Morpholino Antisense Oligomers: Design, Preparation, and Properties,” Antisense & Nucleic Acid Drug Development, 1997, vol. 7 (3), pp. 187-195. |
| Surono, A., et al., “Chimeric RNA/Ethylene-Bridged Nucleic Acids Promote Dystrophin Expression in Myocytes of Duchenne Muscular Dystrophy by Inducing Skipping of the Nonsense Mutation-Encoding Exon,” Human Gene Therapy, 2004, vol. 15 (8), pp. 749-757. |
| Surono, A., et al., “Six Novel Transcripts that Remove a Huge lntron Ranging from 250 to 800 kb are Produced by Alternative Splicing of the 5′ Region of the Dystrophin Gene in Human Skeletal Muscle,” Biochemical and Biophysical Research Communications, 1997, vol. 239 (3), pp. 895-899. |
| Suter, D., et al., “Double-Target Antisense U7 snRNAs Promote Efficient Skipping of an Aberrant Exon in Three Human 13-Thalassemic Mutations,” Human Molecular Genetics, 1999, vol. 8 (13), pp. 2415-2423. |
| Suwanmanee, T., et al., “Restoration of Human 13-Globin Gene Expression in Murine and Human IVS2-654 Thalassemic Erythroid Cells by Free Uptake of Antisense Oligonucleotides,” Molecular Pharmacology, 2002, vol. 62 (3), pp. 545-553. |
| Takeshima, Y., et al., “Basic Research for Treatment of Duchene Muscular Dystrophy Using Induction of Exon Skipping by Means of Antisense Oligo DNA: Effect of in Vivo Administration in Mice,”, Journal of Japanese Society for Inherited Metabolic Diseases, 1999, vol. 15 (2), 6 pages (with English Translation). |
| Takeshima, Y., et al., “Expression of Dystrophin Protein in Cultured Duchenne Muscular Dystrophy Cells by Exon Skipping Induced by Antisense Oligonucleotide”, The 44th Annual 181 Meeting of the Japan Society of Human Genetics, 8 pages, Nov. 17-19, 1999 (English Translation). |
| Takeshima, Y., et al., “Intravenous Infusion of an Antisense Oligonucleotide Results in Exon Skipping in Muscle Dystrophin mRNA of Duchenne Muscular Dystrophy,” Pediatric Research, 2006, vol. 59 (5), pp. 690-694. |
| Takeshima, Y., et al., “Modulation of In Vitro Splicing of the Upstream Intron by Modifying an Intra-Exon Sequence Which is Deleted from the Dystrophin Gene in Dystrophin Kobe,” The Journal of Clinical Investigation, Feb. 1995, vol. 95 (2), pp. 515-520. |
| Takeshima, Y., et al., “Oligonucleotides Against a Splicing Enhancer Sequence Led to Dystrophin Production in Muscle Cells from a Duchenne Muscular Dystrophy Patient,” Brain & Development, 2001, vol. 23 (8), pp. 788-790. |
| Tanaka, K., et al., “Polypurine Sequences within a Downstream Exon Function as a Splicing Enhancer,” Molecular and Cellular Biology, 1994, vol. 14 (2), pp. 134 7-1354. |
| Taneja, K.L., “Localization of Tri nucleotide Repeat Sequences in Myotonic Dytrophy Cells Using a Single Fluorochrome-Labeled PNA Probe,” BioTechniques, vol. 24, No. 3, pp. 472-476, Mar. 1998. |
| Tennyson, C.N., et al., “The Human Dystrophin Gene Requires 16 Hours to be Transcribed and is Cotranscriptionally Spliced,” Nature Genetics, vol. 9 (2), pp. 184-190, 1995. |
| Thanh, L.T., et al., “Characterization of Revertant Muscle Fibers in Duchenne Muscular Dystrophy, Using Exon-Specific Monoclonal Antibodies against Dystrophin,” American Journal of Human Genetics, 1995, vol. 56 (3), pp. 725-731. |
| Thomsen, R., et al., “Dramatically improved RNA in situ hybridization signals using LNA-modified probes,” RNA, vol. 11, pp. 1745-1748, 2005. |
| Thomson Reuters Integrity, “Dystrophin gene (DMD) expression inhibitor PR0-051,” ⋅ Prous Integrity, XP002677703, Mar. 8, 2012. |
| Tian, H., et al., “Selection of Novel Exon Recognition Elements from a Pool of Random Sequences,” Molecular and Cellular Biology, Nov. 1995, vol. 15 (11), pp. 6291-6298. |
| Treat-NMD, Neuromuscular Network, Newsletter No. 24, 6 pages, Jan. 11, 2008. |
| Tsuchida, K., “The Role of Myostatin and Bone Morphogenetic Proteins in Muscular Disorders,” Expert Opinion of Biological Therapy, 2006, vol. 6 (2), pp. 147-154. |
| United States Court of Appeals for the Federal Circuit, Academisch Ziekenhuis Leiden v. University of Western Australia, Notice Forwarding Certified List, Appeal No. 2016-2262, Aug. 5, 2016, 18 pages [Patent Interference No. 106,007 (RES)]. |
| United States Court of Appeals for the Federal Circuit, Brief of Appellant University of Western Australia, 223 pages, dated Jan. 23, 2017 [Interference No. 106,013). |
| United States Court of Appeals for the Federal Circuit, Principal Brief of Appellant Academisch Ziekenhuis Leiden, 135 pages, filed Jan. 23, 2017 [Interference Patent No. 106,007]. |
| United States Court of Appeals for the Federal Circuit, Principal Brief of Appellant Academisch Ziekenhuis Leiden, 80 pages, filed Jan. 23, 2017 [Patent Interference No. 106,008]. |
| United States Patent and Trademark Office, Office Action for U.S. Appl. No. 11/233,495, dated Jun. 25, 2009, 11 pages. |
| United States Patent and Trademark Office, Office Action for U.S. Appl. No. 10/395,031, 11 pages, dated Apr. 2, 2009. |
| United States Patent and Trademark Office, Office Action for U.S. Appl. No. 10/395,031, 15 pages, dated Nov. 30, 2006. |
| United States Patent and Trademark Office, Office Action for U.S. Appl. No. 10/395,031, 16 pages, dated Feb. 6, 2006. |
| United States Patent and Trademark Office, Office Action for U.S. Appl. No. 10/395,031, 20 pages, dated Aug. 23, 2007. |
| United States Patent and Trademark Office, Office Action for U.S. Appl. No. 10/395,031, 20 pages, dated Jul. 8, 2005. |
| United States Patent and Trademark Office, Office Action for U.S. Appl. No. 10/395,031, 29 pages, dated May 30, 2008. |
| United States Patent and Trademark Office, Office Action for U.S. Appl. No. 10/395,031, 7 pages, dated Oct. 16, 2009. |
| United States Patent and Trademark Office, Office Action for U.S. Appl. No. 11/233,495, 14 pages, dated Dec. 1, 2008. |
| United States Patent and Trademark Office, Office Action for U.S. Appl. No. 11/233,507, 12 pages, dated Mar. 19, 2008. |
| United States Patent and Trademark Office, Office Action for U.S. Appl. No. 11/233,507, 16 pages, dated Jun. 15, 2007. |
| United States Patent and Trademark Office, Office Action for U.S. Appl. No. 11/233,507, 17 pages, dated May 29, 2009. |
| United States Patent and Trademark Office, Office Action for U.S. Appl. No. 11/233,507, 17 pages, dated Nov. 12, 2008. |
| United States Patent and Trademark Office, Office Action for U.S. Appl. No. 11/982,285, 16 pages, dated May 4, 2009. |
| United States Patent and Trademark Office, Office Action for U.S. Appl. No. 11/982,285, 22 pages, dated Sep. 18, 2009. |
| University of Western Australia, Academisch Ziekenhuis Leiden v. University of Western Australia, “Brief of Appellee University of Western Australia,” 76 pages, Mar. 6, 2017 [Interference No. 106,007]. |
| University of Western Australia, Academisch Ziekenhuis Leiden v. University of Western Australia, “Response Brief of Appellee University of Western Australia,” 51 pages, Mar. 6, 2017 [Interference No. 106,008]. |
| University of Western Australia, Academisch Ziekenhuis Leiden v. University of Western Australia, University of Western Australia v. Academisch Ziekenhuis Leiden, “Reply of University of Western Australia in Support of It's Motion to Designate as Companion Cases to Extend the Briefing Schedules,” 8 pages, Nov. 21, 2016 [Interference Nos. 106,007, 106,008, 106,013]. |
| University of Western Australia, Reply Brief of Appellant University of Western Australia, US Court of Appeals for the Federal Circuit, Case: 16/1937, 16/2086, 40 pages, Apr. 25, 2017. |
| University of Western Australia, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), University of Western Australia Motion 3 (Requesting an Additional Interference Between UWA U.S. Pat. No. 8,455,636 and Academisch Ziekenhuis Leiden's U.S. Appl. No. 14/248,279), 36 pages, filed Nov. 18, 2014 [Patent Interference No. 106,007 (RES)]. |
| University of Western Australia, University of Western Australia v. Academisch Ziekenhuis Leiden, Corrected Brief of Appellant University of Western Australia, 223 pages, filed Feb. 16, 2017 [Interference No. 106,013]. |
| University of Western Australia, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), University of Western Australia Exhibit List, 10 pages, filed Apr. 10, 2015 [Patent Interference No. 106,007 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), University of Western Australia Exhibit List, 10 pages, filed Apr. 3, 2015 [Patent Interference No. 106,007 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), University of Western Australia Exhibit List as of Feb. 17, 2015, 8 pages, filed Feb. 17, 2015 [Patent Interference No. 106,007 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), University of Western Australia Miscellaneous Motion 4 (to exclude evidence), 21 pages, filed Apr. 10, 2015 [Patent Interference No. 106,007 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), University of Western Australia Motion 1 (for Judgment Under 35 U.S.C. §112(a)), 40 pages, filed Nov. 18, 2014 [Patent Interference No. 106,007 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), University of Western Australia Motion 2 (for Judgment Under 35 U.S.C. §112(b)), 34 pages, filed Nov. 18, 2014 [Patent Interference No. 106,007 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), University of Western Australia Reply 1 (to AZL Opposition 1), 28 pages, filed Apr. 3, 2015 [Patent Interference No. 106,007 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), University of Western Australia Reply 2 (to AZL Opposition 2), 22 pages, filed Apr. 3, 2015 [Patent Interference No. 106,007 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), University of Western Australia Reply 3 (to Institute an Interference), 17 pages, filed Apr. 3, 2015 [Patent Interference No. 106,007 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), University of Western Australia Request for Oral Argument, 4 pages, filed Apr. 10, 2015 [Patent Interference No. 106,007 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. No. 8,455,636) v. Acadernisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), University of Western Australia List of Proposed Motions, 7 pages, filed Sep. 10, 2014 [Patent Interference No. 106,007 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. No. 8,486,907) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 14/198,992), University of Western Australia Motion 1 (to Maintain Interference Between UWA U.S. Pat. No. 8,486,907 and Academisch Ziekenhuis Leiden's U.S. Appl. No. 14/198,992), 45 pages, filed Nov. 18, 2014 [Patent Interference No. 106,013 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. No. 8,486,907) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 14/198,992), University of Western Australia Response to Order to Show Cause, 28 pages, filed Jul. 20, 2015 [Patent Interference No. 106,013 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), University of Western Australia Objections (to Opposition Evidence), 15 pages, filed Feb. 24, 2015 [Patent Interference No. 106,007 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), University of Western Australia Opposition 1 (Regarding Patentability Under 35 U.S.C. § 102/103), 38 pages, filed Feb. 17, 2015 [Patent Interference No. 106,007 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), University of Western Australia Opposition 2 (to Retain UWA's Benefit of AU 2004903474), 37 pages, filed Feb. 17, 2015 [Patent Interference No. 106,007 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), University of Western Australia Opposition 3 (Regarding Patentability Under 35 U.S. C.§ 101), 22 pages, filed Feb. 17, 2015 [Patent Interference No. 106,007 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495), University of Western Australia Opposition 4 (to deny entry of AZL's Proposed New Claims 104 and 105), 36 pages, filed Feb. 17, 2015 [Patent Interference No. 106,007 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), University of Western Australia Exhibit List as of Apr. 10, 2015, 10 pages, filed Apr. 10, 2015 [Patent Interference No. 106,008 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), University of Western Australia Exhibit List as of Apr. 3, 2015, 10 pages, filed Apr. 3, 2015 [Patent Interference No. 106,008 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), University of Western Australia Exhibit List as of Feb. 17, 2015, 8 pages, filed Feb. 17, 2015 [Patent Interference No. 106,008 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), University of Western Australia Miscellaneous Motion 4 (to exclude evidence), 21 pages, filed Apr. 10, 2015 [Patent Interference No. 106,008 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), University of Western Australia Opposition 1 (Regarding Patentability Under 35 U.S.C. § 102/103), 39 pages, filed Feb. 17, 2015 [Patent Interference No. 106,008 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), University of Western Australia Opposition 2 (to Retain UWA's Benefit of AU 2004903474), 31 pages, filed Feb. 17, 2015 [Patent Interference No. 106,008 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), University of Western Australia Opposition 3 (Regarding Patentability Under 35 U.S.C. § 101), 22 pages, filed Feb. 17, 2015 [Patent Interference No. 106,008 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), University of Western Australia Opposition 4 (to deny entry of AZL's Proposed New Claims 30 and 31), 36 pages, filed Feb. 17, 2015 [Patent Interference No. 106,008 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), University of Western Australia Reply 1 (to AZL Opposition 1 ), 28 pages, filed Apr. 3, 2015 [Patent Interference No. 106,008 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), University of Western Australia Reply 2 (to AZL Opposition 2), 22 pages, filed Apr. 3, 2015 [Patent Interference No. 106,008 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), University of Western Australia Reply 3 (for judgment under 35 U.S.C. §135(b)), 19 pages, filed Apr. 3, 2015 [Patent Interference No. 106,008 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), University of Western Australia Request for Oral Argument, 4 pages, filed Apr. 10, 2015 [Patent Interference No. 106,008 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. Nos. 7,960,541, 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), University of Western Australia List of Proposed Motions, 6 pages, filed Sep. 10, 2014 [Patent Interference No. 106,008 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), University of Western Australia Motion 1 (for Judgment Under 35 U.S.C. §112(a)), 38 pages, filed Nov. 18, 2014 [Patent Interference No. 106,008 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), University of Western Australia Motion 2 (for Judgment Under 35 U.S.C. §112(b)), 32 pages, filed Nov. 18, 2014 [Patent Interference No. 106,008 (RES)]. |
| University of Western Australia, University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), University of Western Australia Motion 3 (for judgment that Claims 11-12, 14-15, and 17-29 of U.S. Appl. No. 13/550,210 are barred under 35 U.S.C. §135(b)); 25 pages, filed Nov. 18, 2014 [Patent Interference No. 106,008]. |
| University of Western Australia, University of Western Australia v. Academisch Ziekenhuis Leiden, Motion of Appellant University of Western Australia to Stay Appeal Pending Appeals in Two Related Interferences, Document 4-1, 7 pages, entered May 6, 2016 [Patent Interference No. 106,013] [Civil Action No. 2016-1937]. |
| University of Western Australia, University of Western Australia, (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210), University of Western Australia Objections (to Opposition Evidence), 15 pages, filed Feb. 24, 2015 [Patent Interference No. 106,008 (RES)]. |
| USPTO Board of Patent Appeals and Interferences Standing Order, 81 pages, entered Mar. 8, 2011. |
| USPTO Board of Patent Appeals and Interferences. Order—Motion Times—37 C.F.R., §41.104(c) 6 pages, entered Jul. 18, 2014. |
| Van Deutekom, J.C., “Declaration of Dr. JCT van Deutekom,” EP1619249, 2 pages, Aug. 1, 2013. |
| Van Deutekom, J.C., “Declaration of JCT van Deutekom,” EP1619249, 6 pages, Jan. 7, 2014. |
| Van Deutekom, J.C., Declaration of Dr. Judith van Deutekom, 8 pages, EP 1 619 249, Jun. 10, 2014. |
| Van Deutekom, J.C., et al., “Advances in Duchenne Muscular Dystrophy Gene Therapy,” Nature Reviews Genetics, Oct. 2003, vol. 4 (10), pp. 774-783. |
| Van Deutekom, J.C., et al., “Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells,” Human Molecular Genetics, vol. 10, No. 15, pp. 1547-1554, 2001. |
| Van Deutekom, J.C., et al., “Local Dystrophin Restoration with Antisense Oligonucleotide PRO051,” The New England Journal of Medicine, 2007, vol. 357 (26), pp. 2677-2686. |
| Van Deutekom, J.C., Transcript of deposition testimony of Dr. Judith van Deutekom taken on Mar. 11, 2015, pertaining to Patent Interference No. 106,007 (RES); relating to U.S. Pat. No. 8,455,636, 169 pages. |
| Van Ommen, G.J., et al., “The Therapeutic Potential of Antisense-Mediated Exon Skipping,” Current Opinion in Molecular Therapeutics, 2008, vol. 10 (2), pp. 140-149. |
| Van Vliet, L., et al., “Assessment of the Feasibility of Exon 45-55 Multiexon Skipping for Duchenne Muscular Dystrophy,” BMC Medical Genetics, 2008, vol. 9 (105), 7 pages. |
| Varani, G., et al., “The G⋅U Wobble Base Pair. A Fundamental Building Block of RNA Structure Crucial to RNA Function in Diverse Biological Systems,” EMBO Reports, 2000, vol. 1 (1), pp. 18-23. |
| Verhaart, I.E., et al., “Prednisolone Treatment Does Not Interfere with 2′-O-Methyl Phosphorothioate Antisense-Mediated Exon Skipping in Duchenne Muscular Dystrophy,” Human Gene Therapy, Mar. 2012, vol. 23 (3), pp. 262-273. |
| Verreaul T, M., et al., “Gene Silencing in the Development of Personalized Cancer Treatment: The Targets, the Agents and the Delivery Systems,” Current Gene Therapy, 2006, vol. 6 (4), pp. 505-533. |
| Vickers, T.A., et al., “Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents. A Comparative Analysis,” The Journal of Biological Chemistry, Feb. 2003, vol. 278 (9), pp. 7108-7118. |
| Wang, B., et al., “Adena-Associated Virus Vector Carrying Human Minidystrophin Genes Effectively Ameliorates Muscular Dystrophy in mdx Mouse Model,” Proceedings of the National Academy of Sciences of the United States of America, 2000, vol. 97 (25), pp. 13714-13719. |
| Wang, Z., et al., “Sustained AAV-Mediated Dystrophin Expression in a Canine Model of Duchenne Muscular Dystrophy with a Brief Course of lmmunosuppression,” Molecular Therapy, vol. 15 (6), pp. 1160-1166, Jun. 2007. |
| Watakabe, A., et al., “The Role of Exon Sequences in Splice Site Selection,” Genes & Development, 1993, vol. 7 (3), pp. 407-418. |
| Watkins, N.E., et al., “Nearest-Neighbor Thermodynamics of Deoxyinosine Pairs in DNA Duplexes,” Nucleic Acids Research, vol. 33 (19), pp. 6258-6267, 2005. |
| Weiler, T., et al., “Identical Mutation in Patients with Limb Girdle Muscular Dystrophy Type 2B or Miyoshi Myopathy Suggests a Role for Modifier Gene(s),” Human Molecular Genetics, 1999, vol. 8 (5), pp. 871-877. |
| Weisbart, R.H., et al., “Cell Type Specific Targeted Intracellular Delivery Into Muscle of a Monoclonal Antibody that Binds Myosin llb,” Molecular Immunology, 2003, vol. 39 (13), pp. 783-789 (Abstract). |
| Wells, K.E., et al., “Enhanced in Vivo Delivery of Antisense Oligonucleotides to Restore Dystrophin Expression in Adult mdx Mouse Muscle,” FEBS Letters, 2003, vol. 552 (2-3), pp. 145-149. |
| Wenk, J., et al., “Quantitation of Mr 46000 and Mr 300000 Mannose 6-Phosphate Receptors in Human Cells and Tissues,” Biochemistry International, 1991, vol. 23 (4), pp. 723-731(Abstract). |
| Wheeler, T.M., et al., “Reversal of RNA Dominance by Displacement of Protein Sequestered on Triplet Repeat RNA,” Science, vol. 325, pp. 336-339, Jul. 2009. |
| Wheway, J.M., et al., “The Dystrophin Lymphocyte Promoter Revisited: 4.5-Megabase lntron, or Artefact?,” Neuromuscular Disorders, 2003, vol. 13 (1), pp. 17-20. |
| Wilton, S., Declaration of Dr. Steve Wilton in Support of Appeal of Opposition Decision to Maintain EP 1619249, dated Aug. 21, 2013, 25 pages. |
| Wilton, S., et al., Excerpts from Prosecution History of Wilton et al., (U.S. Appl. No. 13/902,376), including an Express Abandonment, 67 pages, filed of May 24, 2013. |
| Wilton, S., et al., Excerpts from Prosecution History of Wilton et al. (U.S. Appl. No. 14/178,059), including Preliminary Amendment and Request to Provoke an Interference, 97 pages, 2014. |
| Wilton, S.D., et al., “Antisense Oligonucleotide-induced Exon Skipping Across the Human Dystrophin Gene Transcript,” Molecular Therapy: The Journal of the American Society of Gene Therapy, Jul. 2007, vol. 15 (7), pp. 1288-1296. |
| Wilton, S.D., et al., “Antisense Oligonucleotides, Exon Skipping and the Dystrophin Gene Transcript.,” Acta Myologica, 2005, vol. 24, pp. 222-229. |
| Wilton, S.D., et al., “Specific Removal of the Nonsense Mutation from the mdx Dystrophin mRNA Using Antisense Oligonucleotides,” Neuromuscular Disorders, 1999, vol. 9 (5), pp. 330-338. |
| Wood, Matthew J.A., University of Western Australia (U.S. Pat. No. 8,455,636) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 11/233,495) [Patent Interference No. 106,007 (RES)] and University of Western Australia (U.S. Pat. Nos. 7,960,541 and 7,807,816) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 13/550,210) [Patent Interference No. 106,008 (RES)], University of Western Australia (U.S. Pat. No. 8,486,907) v. Academisch Ziekenhuis Leiden (U.S. Appl. No. 14/198,992) [Patent Interference No. 106,013 (RES)], Second Declaration of Matthew J.A. Wood, M.D., D. Phil., 78 pages, filed Feb. 17, 2015. |
| Wood, Matthew J.A., University of Western Australia (U.S. Pat. Nos. 8,455,636, 7,960,541, 7,807,816, 8,486,907) v. Academisch Ziekenhuis Leiden (U.S. Appl. Nos. 11/233,495, 13/550,210, 14/198,992), Declaration of Matthew J.A. Wood, M.D., D. Phil.—UWA Exhibit 2081, 184 pages, filed Sep. 19, 2014 [Patent Interference Nos. 106,007, 106,008, 106,113 (RES)]. |
| Wright et al. Opposition to EP 2 344 637, Sep. 24, 2015, 28 pages. |
| Wu, B., et al., “Targeted Skipping of Human Dystrophin Exons in Transgenic Mouse Model Systemically for Antisense Drug Development,” PLoS One, vol. 6 (5), 11 pages, 2011. |
| Xu, L., et al., “Potential for Pharmacology of Ryanodine Receptor/Calcium Release Channels,” Annals of the New York Academy of Sciences, vol. 853, pp. 130-148, Sep. 16, 1998. |
| Yen, L., et al., “Sequence-specific Cleavage of Huntingtin mRNA by Catalytic DNA,” Annals of Neurology, 1999, vol. 46 (3), pp. 366-373. |
| Yilmaz-Elis, As., et al., “Inhibition of IL-1 Signaling by Antisense Oligonucleotide-mediated Exon Skipping of IL-1 Receptor Accessory Protein (IL-1 RAcP),” Molecular Therapy—Nucleic Acids, 2013, vol. 2, e66, 8 pages. |
| Yin, H., et al., “Effective Exon Skipping and Restoration of Dystrophin Expression by Peptide Nucleic Acid Antisense Oligonucleotides in mdx Mice,” Molecular Therapy, Jan. 2008, vol. 16 (1), pp. 38-45. |
| Yokota, T., et al., “Antisense Oligo-Mediated Multiple Exon Skipping in a Dog Model of Duchenne Muscular Dystrophy,” Methods in Molecular Biology, vol. 709, pp. 299-312, 2011. |
| Yokota, T., et al., “Efficacy of Systemic Morpholino Exon-Skipping in Duchenne Dystrophy Dogs,” American Neurological Association, 2009, vol. 65 (6), pp. 667-676. |
| Yu, M., et al., “A Hairpin Ribozyme Inhibits Expression of Diverse Strains of Human Immunodeficiency Virus Type 1,” Proceedings of the National Academy of Sciences of the United States of America, 1993, vol. 90 (13), pp. 6340-6344. |
| Yu, R.Z., et al., “Development of an Ultrasensitive Noncompetitive Hybridization-Ligation Enzyme-Linked lmmunosorbent Assay for the Determination of Phosphorothioate Oligodeoxynucleotide in Plasma,” Analytical Biochemistry, vol. 304 (1), pp. 19-25, 2002. |
| Zhang, G., et al., “Efficient Expression of Naked DNA Delivered lntraarterially to Limb Muscles of Nonhuman Primates,” Human Gene Therapy, 2001, vol. 12 (4), pp. 427-438 (Abstract). |
| Zhou, G.Q., et al., “Current Understanding of Dystrophin-Related Muscular Dystrophy and Therapeutic Challenges Ahead,” Chinese Medical Journal, 2006, vol. 119 (16), pp. 1381-1391. |
| Anthony et al., “Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials,” Brain, 134:3547-3559 (2011). |
| Bernasconi et al., “Cortisol increases transfection efficiency of cells,” FEBS Letters, 419:103-106 (1997). |
| Biomarin Press Resease, “BioMarin Announces Withdrawal of Market Authorization Application for Kyndrisa (drisapersen) in Europe,” May 31, 2016. |
| Braun et al., “In vitro and in vivo effects of glucocorticoids on gene transfer to skeletal muscle,” FEBS Letters, 454:277-282 (1999). |
| Bushby et al., “145th ENMC International Workshop: Planning for an International Trial of Steroid Dosage Regimes in DMD (for DMD) Oct. 22-24, 2006, Naarden, The Netherlands,” Neuromuscular Disorders, 17:423-428 (2007). |
| Bushby et al., “Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids Apr. 2-4, 2004, Naarden, The Netherlands,” Neuromuscular Disorders, 14:526-534 (2004). |
| Chan et al., “Antisense oligonucleotides: from design to therapeutic application,” Clin. Exp. Pharmacol. Physiol., 33:533-540 (2006). |
| Cirak et al., “Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study,” Lancet, 378:595-605 (2011). |
| European Patent Office, European Patent Application No. 07119351.0 filed Oct. 26, 2007. |
| Exondys 51™, “Highlights of Prescribing Information,” Eteplirsen label dated Sep. 2016. |
| FDA News Release, “FDA grants accelerated approval to first drug for Duchenne muscular dystrophy,” Sep. 19, 2016. |
| Goemans et al., “Comparison of ambulatory capacity and disease progression of Duchenne muscular dystrophy subjects enrolled in the drisapersen DMD114673 study with a matched natural history cohort of subjects on daily corticosteroids,” Neuromuscular Disorders, 27:203-213 (2017). |
| Hardiman et al., “Methylprednisolone selectively affects dystrophin expression in human muscle cultures,” Neurology, 43:342-345 (1993). |
| Hussein et al., “The effects of glucocorticoid therapy on the inflammatory and dendritic cells in muscular dystrophies,” Int. J. Exp. Path., 87:451-461 (2006). |
| Khan et al., “Corticosteroid therapy in Duchenne muscular dystrophy,” J. Neurol. Sci., 120:8-14 (1993). |
| Manning et al., “What has the mdx mouse model of duchenne muscular dystrophy contributed to our understanding of this disease?,” J. Muscle Res. Cell. Motil., 36(2):155-167 (2015). |
| Manzur et al., “Glucocorticoid corticosteroids for Duchenne muscular dystrophy,” Cochrane Database of Systematic Reviews, 1:1-72 (2008). |
| Merlini et al., “Improving clinical trial design for Duchenne muscular dystrophy,” BMC Neurology, 15:153 (2015). |
| Moxley et al., “Practice Parameter: Corticosteroid treatment of Duchenne dystrophy,” Neurology, 64:13-20 (2005). |
| Muntoni et al., “128th ENMC International Workshop on ‘Preclinical optimization and Phase I/II Clinical Trials Using Antisense Oligonucleotides in Duchenne Muscular Dystrophy’ Oct. 22-24, 2004, Naarden, The Netherlands,” Neuromuscular Disorders, 15:450-457 (2005). |
| Muntoni et al., “Steroids in Duchenne muscular dystrophy: from clinical trials to genomic research,” Neuromuscular Disorders, 12:S162-S165 (2002). |
| U.S. Food and Drug Administration, “FDA Briefing Document: Peripheral and Central Nervous System Drugs Advisory Committee Meeting,” Nov. 24, 2015, NDA 206031, Drisapersen. |
| United States Patent and Trademark Office, U.S. Appl. No. 61/000,670, filed Oct. 26, 2007. |
| USAN Council, “Drisapersen,” Statement on a nonproprietary name adopted by the USAN Council. |
| Wehling-Henricks et al., “Prednisolone decreases cellular adhesion molecules required for inflammatory cell infiltration in dystrophin-deficient skeletal muscle,” Neuromuscular Disorders, 14:483-490 (2004). |
| Wuebbles et al., “Levels of α7 integrin and laminin-α2 are increased following prednisone treatment in the mdx mouse and GRMD dog models of Duchenne muscular dystrophy,” Disease Models & Mechanisms, 6:1175-184 (2013). |
| Alter et al., “Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology,” Nat. Med. 12(2): 175-177 (2006). |
| Kurihara et al., “Muscular Disorders,” Review/Advances in Neurological Therapeutics,5 pages, 2000, 365-369. |
| Kurihara et al., “Muscular Disorders,” Review/Advances in Neurological Therapeutics,4 pages, 2000 (English Translation). |
| Summerton et al., “Morpholino Antisense Oligomers: Design, Preparation, andProperties,” Antisense Nucleic Acid Drug Dev. 7(3): 187-195 (1997). |
| Ito et al. “Identification of Splicing Enhancer Sequences Within Exon Sequences ofDystrophin Gene”, 42nd Convention of Japanese Society for Inherited Metabolic Diseases,Kagoshima, Japan, Nov. 11-13, 1999, Journal of Japanese Society for Inherited MetabolicDiseases, 15(2): # 100, Nov. 1999. |
| Popplewell et al., “Design of Antisense Oligonucleotides for Exon Skipping of theHuman Dystrophin Gene”, BSGT Annual Conference Abstracts, Human Gene Therapy, 19(4):402-422, # P-35, Apr. 2008. |
| Kandimalla, E.R., et al., “Effects of Phosphorothioate Oligodeoxyribonucleotide and Oligoribonucleotides on Human Complement and Coagulation,” Bioorganic & Medicinal Chemistry Letters, vol. 8, No. 16, pp. 2103-2108, 1998. |
| Sironi et al., “Silencer elements as possible inhibitors of pseudoexon splicing”, Nucleic Acids Research, 2004, vol. 32, No. 4, pp. 1783-1791. |
| Graham IR, Hill VJ, Manoharan M, Inamati GB, Dickson G. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides ( splicomers ): target sequence optimisation using oligonucleotide arrays. J Gene Med 2004; 6(10):1149-58. |
| Mathews DH, Sabina J, Zuker M, Turner D H. Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J Mol Biol 1999; 288(5):911-40. |
| Braasch DA, Corey DR. Novel antisense and peptide nucleic acid strategies for controlling gene expression, Biochemistry 2002; 41(14):4503-10. |
| Elayadi AN, Corey D R. Application of PNA and LNA oligomers to chemotherapy. Curr Opin Investig Drugs 2001; 2(4):558-61. |
| Larsen HJ, Bentin T, Nielsen PE. Anti sense properties of peptide nucleic acid. Biochim Biophys Acta 1999; 1489(1):159-66. |
| Wahlestedt C, Salmi P, Good L, et al. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci USA 2000; 97(10):5633-8. |
| Govindaraju et al., “Backbone-extended pyrrolidine peptide nucleic acids (bepPNA): design, synthesis and DNA/RNA binding studies”, Chemical Communications, 2005, pp. 495-497. |
| Egholm et al., “PNA Hybridizes to Complementary Oligonucleotides Obeying the Watson-Crick Hydrogen-Bonding Rules”, Nature, 1993, vol. 365, pp. 566-568. |
| Yokota et al., “Optimizing exon skipping therapies for DMD,” Acta Myol. 26(3): 179-184 (2007). |
| Number | Date | Country | |
|---|---|---|---|
| 20190100754 A1 | Apr 2019 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15289053 | Oct 2016 | US |
| Child | 16024558 | US | |
| Parent | 14631686 | Feb 2015 | US |
| Child | 15289053 | US | |
| Parent | 13094571 | Apr 2011 | US |
| Child | 14631686 | US | |
| Parent | PCT/NL2009/050113 | Mar 2009 | US |
| Child | 13094571 | US | |
| Parent | PCT/NL2008/050673 | Oct 2008 | US |
| Child | PCT/NL2009/050113 | US |
